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Radiochemical diagnostics and therapeutics benefit from pairing with a compliment second 
imaging modality. However, methods to radiolabel and link these molecules to targeting vectors 
are problematic. In this dissertation, I explored new radiosynthetic strategies for producing 
fluorophore-based bimodal agents and new bioconjugation reagents for antibody drug conjugation 
with improved in vivo stability. 
18F-radiolabeled 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) fluorophores are 
hypothetically ideal bimodal imaging candidates. Preliminary experiments focused on facilitating 
19F/18F-transfluorination of Pseudomonas aeruginosa-selective BODIPY dye, CDy11, using 
Lewis acidic [18F]F-BODIPY labeling strategies described in literature. However, the 
conventionally applied tin(IV)-chloride (SnCl4) Lewis acid’s instability affords reaction yield 
variability, and further promoted degradation of the CDy11. Thus, research transitioned towards 
investigating an alternative Lewis acid. To our knowledge, we are the first to use hydrated 
magnesium nitrate [Mg(NO3)2] as an air-stable substitute for promoting 
18F-fluorination of 
commercially-available BODIPY dyes. Order of reagent addition significantly affected the 
19F/18F-isotopic exchange reaction; with addition of azeotropically dried [18F]F-TBAF to a mixture 
of the commercial dye and Lewis acidic agent proving most effective. 19F/18F-transfluorination 
was achieved using both SnCl4 and Mg(NO3)2 to varying degrees. Increasing the equivalences of 
applied Mg(NO3)2 salt generally improved radiochemical yields.  
Bioconjugation chemistry enables the covalent attachment of molecules of interest to larger 
proteins such as antibodies. While conjugation with thiol groups (cysteine) in antibodies is 
common, conventional maleimide-based coupling agents are prone to in vivo hydrolysis. Price lab 
research efforts sought to develop radioimmunoconjugates that operate through two 
phenyloxadiazolyl methyl sulfone (DiPODS) functionality to form irreversible bonds with 
antibody cysteine pairs. My contribution was to assist in synthesizing several of the multistep 
synthesis products and apply spectroscopic methods towards analysis of the initial step’s product 
mixture, which was hypothesized to exist as a rotameric mixture. Several intermediate agents were 
 iii 
successfully synthesized to produce the desired DIPODS end product. The three components of 
the 5-[[(1,1-dimethylethoxy)carbonyl]amino]-1,3-dimethyl ester (compound 1)product mixture 
were attributed to an inseparable mixture of rotamers, doubly-di-tert-butyl decarbonate (Boc)-
protected derivative of the compound, and imidic acid tautomers using spectroscopic methods 
including variable temperature 1H NMR. Lastly, an additional chemical species was observed via 
1H NMR as temperature was increased to 75 °C and attributed to a second set of product rotamers. 
Ultimately, this thesis served to improve future radiotherapeutic agents and radio-diagnostics 
through the investigation of alternative and reproducible [18F]F-BODIPY labeling strategies and 
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Elements vary from one another by virtue of their characteristic atomic numbers or the 
number of protons associated with a specific atom. However, while the atomic number may 
classify two atoms as being of the same element, they may differ from one another based on the 
number of neutrons held at their cores. The nucleus is comprised of protons and neutrons, and 
when the number of protons remains the same but the number of neutrons varies, the result is 
different isotopes of the same element. Some isotopes are radioactive (radionuclides, 
radioisotope), which are isotopic variants with an unfavorable nuclear ratio of protons and 
neutrons, making the atom unstable. As such, unstable nuclei stabilize themselves through 
spontaneous transformation to alter the number of neutrons and protons at their core, emitting 
radiation in the process.  
The type of energy emitted by a radioactive substance depends on how the radionuclide 
stabilizes itself. For example, heavy unstable nuclei opt to reduce their number of protons and 
neutrons through alpha-decay, wherein an alpha-particle ( α, He2
4
2
4 ) is emitted. Alpha-particles 
undergo high energy expulsion from the nucleus but quickly lose energy as the particle travels in 
space. The alpha particle’s trajectory can thus be stopped by the outermost layer of skin or by a 
piece of paper. Nuclei that undergo beta-decay release smaller, more energetic particles. The 
charge of the particle depends on the nature of the nuclei from which it came. Neutron-rich species 
will convert a neutron into a proton, expelling an electron ( β−1
0 ), while proton-rich species, as will 
be discussed in further detail later, convert a proton into a neutron via non-emissive electron 
capture or positron emission ( β+1
0 ) processes. The lighter beta-particles travel with greater energy 
than alpha-particles but can still be halted by aluminum foil or a ~1 cm thick layer of glass or 
plastic. Finally, gamma-radiation, the emission of pure electromagnetic energy, is released as an 
excited unstable radioisotope rearranges itself into a lower excitation state.1 Gamma-photons (γ) 
travel with such high energy, they readily pass through the barriers that would halt alpha- and beta-
particles and even pass through the human body with minimal attenuation. Consequently, denser 
materials like lead and concrete are needed to shield from their emission (Figure 1.1). 
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Figure 1.1. A) Illustration of an unstable nucleus stabilizing and releasing energy in the 
process. B) Three potential energy emission products and their penetrance through increasingly 
dense materials. Figure adapted from (Issard, 2015).2 
Radiochemistry is the study of naturally occurring and man-made radionuclides and 
focuses on the following: 1) investigating the synthetic routes by which radionuclides are produced 
and/or incorporated into molecular frameworks, and 2) utilizing the emissive properties of 
radioactive substances for the purpose of investigating chemical and biochemical processes in the 
form of probes/diagnostics or altering the surrounding environment as biomedical treatments.3 4 
Radiochemical techniques are used in numerous scientific domains such as materials science, 
pharmaceutical research, and environmental sciences to name a few.5 These research efforts vary 
significantly in their motivations and assess drastically differing systems. What is more, as the 
focus of research continuously changes, the radiochemistry associated with evaluating those 
interests must be modified to accommodate these differing needs. Increasingly specific 
radiochemical probes are needed to assess wider arrays of chemical and biological phenomena. 





















the demand for highly replicable radiolabeling methods for larger scale production. The success 
of imaging agents as well as the potency of theranostic agents can be ameliorated by improving 
the stability of their delivery scaffolds. The following will discuss matters pertaining to these issues 
in further depth. 
1.1. Fluorine-18 ([18F]F-). 
 PET imaging techniques apply an array of radioisotopes to investigate biological processes. 
Of these, fluorine-18 ([18F]F-) is considered an attractive β+-emitter for molecular imaging by 
virtue of the numerable advantages that its nuclear and physical properties provide. 
1.1.1. Fluorine in Medicine. 
Fluorine plays a vital role in medicinal chemistry, with fluorinated compounds comprising 
nearly a third of the best-selling pharmaceuticals. The enthalpic strength of the carbon-fluorine 
bond is comparatively stronger than that of carbon-hydrogen bonds (C-F, 112 kcal/mol vs C-H, 98 
kcal/mol), contributing to fluorinated compounds’ superior metabolic stability and bioavailability. 
Furthermore, fluorination of aromatic biomolecules increases their lipophilicity and consequently 
improves their tissue absorption and distribution.6 7 
1.1.2. Fluorine-18 Radioisotope. 
Radioactive decay of fluorine-18 occurs as the unstable “proton rich” nucleus of the parent 
fluorine-18 atom stabilizes by converting one of its protons into a neutron. This change is termed 
β+-decay (positron decay) and is achieved through either electron capture or by positron emission 
processes. 
Electron capture occurs as an electron from a proton rich atom’s surrounding inner shell is 
drawn into its nucleus to combine with a proton and form a neutron; ejecting a chargeless neutrino 
(ve) in the process of producing the stable oxygen-18 daughter nuclide (Scheme 1.1). While a 
small number of fluorine-18 atoms do undergo electron capture, most of them stabilize their nuclei 
through positron emission.  
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Scheme 1.1. Radioactive decay of fluorine-18 ( 𝐹9
18 ) to oxygen-18 daughter atom ( 𝑂8
18 ) 
through electron ( 𝑒−1
0 ) capture. 
Positron emission occurs as a proton from the unstable nucleus is converted into a neutron 
through release of radiation in the form of a positron particle (β+), the antiparticle of an electron, 
and a neutrino to yield the stable daughter nuclide (Scheme 1.2 A). While this is not always the 
case, the daughter atoms produced through these β+-decay processes, while stable, might be in an 
excited electronic state. As they descend to a more stable ground state, the daughter atoms release 
a gamma photon (γ) (Scheme 1.2 B). 
 
Scheme 1.2. A) Radioactive decay of fluorine-18 atom ( F9
18 ) to oxygen-18 ( O9
18 ) through 
positron emission. B) Positron emission process converting proton-rich nucleus’s proton ( p1
1 ) into 
a neutron ( n0
1 ) causing release of a positron (β+), a chargeless neutrino (ve), and occasionally a 
gamma photon if an excited state daughter atom is produced (γ). 
Fluorine-18 is frequently used for molecular imaging due to its short half-life of 109.7 
minutes and short positron ranges; with maximum and average positron traveling ranges of 2.4 
mm and 0.6 mm in water, respectively. It is widely considered a “gold-standard” within the field 
of nuclear diagnostics.8 9 Fluorine is used as a bioisosteric substitute for atoms sharing similar 
physical and chemical properties such as size and electronegativity. As such, fluorine-18 serves as 
a suitable substitute for the hydroxyl groups of biomolecules by virtue of their similar Pauling 
electronegativity values; with values of ~3.55 and ~4.0 for hydroxide and fluoride functional 
groups, respectively.10 11 Likewise, fluorine-18 serves as a isosteric replacement for hydrogen as 
they share comparable van der Waal’s radii of 1.2 Å and 1.35 Å for hydrogen and fluorine, 
respectively.12 In correspondence with these relationships, fluorine-18 is frequently incorporated 
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into small molecules, peptides, aptamers, and proteins by replacing a hydrogen, hydroxide, or 
specialized labile leaving group via nucleophilic or electrophilic substitution with a reactive 
precursor. A common example of this is the production of fluorine-18-labeled fluorodeoxyglucose 
([18F]F-FDG); a C2 analogue for glucose.  
[18F]F-FDG is a widely applied PET imaging agent used to identify a variety of 
hypermetabolic tumours and to assess the efficacy of oncological treatments. The premise for 
FDG’s frequent application stems from the body’s use of glucose as a common source of energy. 
Cancer cells require substantially high quantities of glucose to sustain their hyperactive growth 
and replication. In addition to their ability to obtain large amounts of glucose through induction 
processes such as angiogenesis, malignant cells circumvent slower mitochondrial glucose 
metabolic processes and preferentially apply the quicker glycolysis route of ATP production in 
what is known as the Warburg effect.13  While FDG and glucose are both incorporated into the 
cancers through glucose transporters, the C2-fluorination that differentiates FDG from glucose 
also prevents the modified sugar from fully metabolizing, resulting in its accumulation within the 
cancerous cells. 13  FDG is frequently produced using both nucleophilic and electrophilic 
substitution methods as shown in Scheme 1.3.14 
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Scheme 1.3. Synthesis of D-[18F]-fluorodeoxyglucose ([18F]F-FDG) through: a) 
nucleophilic and B) electrophilic substitution strategies. 
1.2. ( 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) BODIPY Dyes. 
Initially reported in 1969 by Triebs and Kreuser,15 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene, 
hereafter referred to as (BODIPY) and its associated derivatives are considered highly versatile 
fluorescent agents. 16  They are currently applied in numerous areas of research including 
photodynamic therapy, 17  energy transfer technologies, 18  and fluorescent diagnostics. 19 The 
structural framework of BODIPY (Figure 1.2) consists of a central six-membered ring flanked by 
two pyrrole sides.20 21 The planar quasi-aromatic framework of the BODIPY core has strong 
chromophoric π-electron delocalization. 22  23  As such, the highly conjugated system displays 
unique spectroscopic properties including a high fluorescence quantum yield, relatively short 
Stokes Shift, and intense/narrow emission peaks.24 25 26 Furthermore, BODIPY dyes are soluble in 
most organic solvent and possess superior thermal and photo-stability with respects to other 





Figure 1.2. Chemical structure of the BODIPY core. 
1.2.1. Optical Imaging. 
Optical imaging has proven to be a dynamic platform for in vivo molecular imaging.28 
Compared to other visualization techniques, optical imaging offers superior spatial and temporal 
resolution while allowing for economical and non-invasive assessments of functional 
abnormalities at the subcellular level.29 30 Although these features are true for in vitro microscopy, 
optical imaging agents are notably limited in vivo by deep tissue light attenuation, and interference 
caused by autofluorescence from some tissue components.31 
Optical methods apply fluorescent and bioluminescent sensors to probe various 
biochemical processes. Diagnostic information is then inferred using an optical camera to detect 
the fluorophores’ location, intensity, and associated activities.32 As optical imaging technologies 
continue to progress, the synthesis of novel fluorophores such as BODIPY’s has become an 
increasingly active field of research.33 
1.2.2. Positron Emission Tomography (PET). 
Positron emission tomography (PET) is used for non-invasive early disease diagnosis. PET 
diagnostics can assess biological processes at the subcellular level, allowing physiological changes 
to be mapped within the body before they anatomically manifest.34 It is important to note that 
although PET is a functional imaging technique capable of probing biological processes, the 
resolution of PET cannot obtain images at subcellular resolutions. PET images are typically in the 
range of 0.5-3 mm spatial resolution, depending on the radionuclide and PET camera. 
8 
PET imaging begins by administering a β+-emitting radioactive tracer into the biological 
system of interest. As the radionuclide decays, the emitted positrons travel through the surrounding 
medium (for fluorine-18 the average distance travelled is 0.6 mm when H2O is used as a surrogate 
for cellular tissue)35 before losing kinetic energy and subsequently annihilating upon impact with 
an electron (e-) from the environment. Upon annihilation, two photons (γ) are produced and travel 
in nearly 180° opposing trajectories where the two time-coincident events of the high-energy 
photons are detected by a cylindrical array of detectors placed around the subject system (Figure 
1.3). For all positron annihilations, regardless of the parent radionuclide and the distance traveled 
by the positron, the resulting photons possess a characteristic energy of 511 keV. The sites at which 
the annihilation events take place and, by association, the radiotracer to which the positron emitter 
is bound, is calculated using the spatial information obtained from millions of these positron 
emission/annihilation events detected by the surrounding detectors.36 37 
 
Figure 1.3. Schematic representation of the PET-imaging process. Figure adapted from 
(Berger, 2003 and Vaquero et al., 2013).38 39 
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1.2.3. Optical/PET Dual-Modality. 
Optical imaging techniques provide attributes complementary to PET (Table 1.1). While 
optical methods offer subcellular level resolution of molecular environments, fluorescent signals 
are diminished in deeper layers of tissue. In contrast, the photons generated from positron 
annihilation are gamma rays and possess enough energy to pass through biological tissue with 
minimal attenuation, enabling analysis of deep tissues. However, while nuclear imaging methods 
allow for the molecular processes to be assessed, PET diagnostics are limited by their lower spatial 
resolution (>1 mm). 40 As such, optical- and PET- imaging methods can be coupled with one 
another to optimally assess biological activity via synergistic exploitation of their complementing 
attributes. 41 BODIPY fluorophores present ideal candidates for bimodality. By subjecting the 
existing BF2 structural component of their core framework to radiofluorination techniques, a 
positron emitting [18F]F-BODIPY product is produced. What is more, the optical activity and 
chemical properties of the precursor are unchanged as the structural composition of the starting 
material and the radiolabeled product remains the same. 
Table 1.1. Summary of the advantages & disadvantages of Optical and PET imaging 
techniques. 
 
1.3. [18F]-Labeling Strategies for BODIPY Dyes. 
1.3.1. Brønsted-Lowry Acid/Base Theory 
 Established in 1923 by chemists Johannes Nicolaus Brønsted and Thomas Martin Lowry,42 
43 the Brønsted-Lowry theory of acids and bases outlines the relationship between acids and bases 
Optical Imaging Positron Emission Tomography (PET) 
High Spatial & Temporal Resolution Deep Tissue Imaging 
Optical Contrast Non-Invasive 
Inexpensive Highly Sensitive 
Poor Tissue Penetration  Limited Anatomical Resolution (>1 mm) 
Photobleaching of Dyes Limitations of Continual Decay (t1/2) 
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as the proton transfer between chemical species in liquid and gas reaction mediums. 44  By 
definition, Brønsted-Lowry acids and bases are defined as proton (H+) donors and acceptors 
respectively.45 As shown in Figure 1.4, the proton transfer between a Brønsted acid (H-A) and 
base (B) produces a conjugate base (A-) and acid (H-B+) species. 
 
Figure 1.4. Illustrated Brønsted-Lowry acid-base reaction scheme.  
1.3.2. Brønsted-Lowry Acid-Assisted 19F/18F-Isotopic Exchange. 
(Hendricks et al., 2012) 46  had previously reported a two-pot synthetic route for the 
production of [18F]F-BODIPY where a fluoride from the R-BF2-moiety was abstracted by 
trimethylsilyl trifluoromethanesulfonate (TMSOTf) to afford an activated BODIPY-triflate 
intermediate. 19F/18F-trans fluorination was subsequently facilitated when the triflate-intermediate, 
stabilized by 2, 6-lutidine, was subjected to tert-butanol and triflic anhydride. In the presence of 
free fluorine-18, these Brønsted acidic conditions reportedly afforded the desired [18F]-labeled 
BODIPY dye in 67% radiochemical yield (Scheme 1.4). While Brønsted-Lowry acid-catalyzed 
19F/18F-exchange reactions are capable of successfully facilitating the desired reaction, the low pH 




Scheme 1.4. Two-step radio-synthetic preparation of [18F]F-BODIPY dye as performed by 
(Hendricks et al., 2012), showing a two-step reaction with a) synthesis of the BODIPY-triflate 
intermediate from trimethylsilyl trifluoromethanesulfonate (TMSOTf), and b) radiofluorination of 
BODIPY-triflate intermediate as facilitated by Brønsted-acidic conditions. Tetrabutylammonium 
bicarbonate (TBAB) is applied in the above reaction process as a phase transfer agent. 
1.3.3. Lewis Acids/Base Theory. 
 Brønsted-Lowry’s definition of acid/base interactions pertains exclusively to reactions 
involving proton exchange. However, Gilbert N. Lewis theorized a more general definition of the 
acid/base dynamic wherein Lewis acids are distinguished by their ability to accept a pair of 
electrons and Lewis bases by their ability to donate them.47 While Brønsted acids (H+) can be 
considered Lewis acids given their ability to donate protons and effectively gain the electrons, 
Lewis’s interpretation of acids and bases expands on Brønsted and Lowry’s conceptualization to 
explain the formation of coordination complexes from ligating species (Lewis bases) and metal 
cations (Lewis acids).48 The reaction between a Lewis acid and base forms a coordinate covalent 
bond between the two reagents as electrons, usually from the base’s highest occupied molecular 
orbital (HOMO), are shared between itself and the Lewis acid’s lowest unoccupied molecular 
orbital (LUMO),49 producing a Lewis acid-base adduct (Scheme 1.5). 
 
Scheme 1.5. Reaction of boron trifluoride (Lewis acid) with ammonia (Lewis Base) to 
form a Lewis acid-base adduct; ammonia boron fluoride.50 
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1.3.4. Hard Soft Lewis Acid Base (HSAB) Theory & Lewis Acid Selection. 
Pearson’s hard soft acid base (HS B) theory is often used when discussing the trends in Lewis 
acid/base interactions. HSAB relates the affinities of acids and bases for one another to the degree 
by which each of the chemical species experiences distortion of their electron cloud in the presence 
of an electric field; otherwise known as the atom or ion’s polarizability. The element’s 
polarizability depends on the degree of dispersion between electrons within the atom or ion’s 
electron cloud. A diffuse field of electron is easily distorted in the presence of nearby electric 
forces and thus distinguishes the associated atom’s nature as “soft”. Conversely, atoms that hold 
their surrounding electrons near the nucleus will experience less polarization and are referred to as 
having a “hard” electron shell. For metal cations, a general trend is that higher oxidation states 
correspond with a “harder” ion.  
Several characteristics of hard and soft acids and bases are outlined in Table 1.2 The 
complementary natures observed of hard electron shell-bearing acids and bases rationalizes their 
high affinity for one another to form strong ionic interaction. Likewise, the compatible attributes 
of soft acids and soft bases lead to favorable interactions with one another and native bond 
formation. 51 Based on these characteristic properties, fluoride anions are considered hard bases 
and preferentially interact with hard Lewis acids of low polarizability. In accordance with this, 
light metal ions hosting large positive charges with respect to their relatively small ionic radii serve 
as ideal Lewis acidic agents to abstract fluoride from the BF2-moiety of BODIPY dyes. Examples 
of hard metal ions include magnesium (Mg2+), tin(II) (Sn2+) and, to a greater extent, tin(IV) (Sn4+) 






Table 1.2. Characteristic attributes of hard and soft acids and bases. 
Property Hard Soft 
- Acids Bases Acids Bases 
Polarizability Low Low High High 



















1.3.5. Lewis Acid-Assisted 19F/18F-Isotopic Exchange. 
 The Lewis acid-assisted 18F/19F-isotopic exchange has become the dominant means for 
promoting transfluorination of BODIPY molecules (Scheme 1.6).53 During their initial study, (Liu 
et al., 2013) had selected Lewis acids of intermediate strength as determined by Gutmann’s anion 
accepting scale.54 Of the Lewis acids assessed, SnCl4 and TiCl4 had shown the greatest success, 
achieving respective radiochemical conversion values of >95% and 90% for the unlabeled dye 
quickly (10 min) under mild conditions (25 °C). As such, they remain the primary means of choice 
for researchers seeking to employ BODIPY-based bimodal imaging agents. 
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Scheme 1.6. 19F/18F-Radioisotopic exchange reaction as described by (Liu et al., 2013), 
wherein tetrabutylammonium bicarbonate (TBAB) acts as a phase transfer catalyst and various 
Lewis Acids were applied as catalysts to facilitate transfluorination of reagent 1+.53 
1.4. Antibody Drug Conjugates.  
Although not directly related to BODIPY dyes and their radiochemistry, antibodies are very 
common targeting vectors used in molecular imaging and nuclear medicine. Bioconjugation 
chemistry is used to attach “payloads” to antibodies such as chelators/radiometals, dyes, or even 
chemotherapy drugs. In this way, a wide variety of antibodies can be transformed into imaging 
agents and/or therapeutics.55 With these antibody platforms, the antibody provides receptor-
specific targeting of cellular antigens and the payload is carried by the antibody of these cells 
via the covalent bioconjugation linkages. As such, antibody-drug conjugates are promising drug 
and diagnostic delivery platforms that offer selective administration of cytotoxic molecules 
targeted antigens.56 57 58 
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The bulk of the antibody conjugate’s structure consists of either a laboratory-engineered 
human monoclonal or humanised antibody scaffold with high affinity and selectivity for a target 
antigen.59 Molecular chains (linkers/spacers) covalently binds the active compound to solvent-
exposed amino acids present in the antibody, forming an immunoconjugate (Figure 1.5). The 
antibody delivery platform’s biological compatibility and receptor-selectivity acts as a prodrug 
and ultimately reduces systemic toxicity and improves the pharmacokinetic and 
pharmacodynamics properties of the drug.60 Ideal ADCs only release their drug payload inside 
of or in the local environment of cancer cells.  
 
Figure 1.5. Illustration of immunoconjugate composition. 
1.4.1. Cleavable and Non-Cleavable Linkers. 
The design and structure of chemical linkers are crucial to the success of antibody drug 
conjugates. The linker requires sufficient stability so as not to prematurely release the active 
compound and adversely affect healthy tissues while the antibody drug conjugate circulates 
through the bloodstream. Once inside the target cell, the linker must liberate the bound payload 
efficiently. 61  Linkers are widely categorized as being either “cleavable” or “non-cleavable”. 







circulating blood and the cytoplasm of the target cells such as changes in pH and reducing 
environment or by cells’ lysosomal enzymes. The bonds of non-cleavable linkers are non-
susceptible to proteolytic degradation and thus more stable in comparison to their cleavable 
counterparts. Instead, the active diagnostic/therapeutic compound is afforded through the complete 
degradation of the antibody scaffold into its fundamental amino acids via cytosolic and lysosomal 
proteases.62 
The best choice of ADC linker ultimately depends on the selected antibody, the 
biochemical properties of the attached payload, and the desired course of action. Cleavable linkers 
are advantageous for treating heterogeneous malignancies through delivery of cytotoxic payloads 
that yield membrane-permeable metabolites. As such, cleavably-linked antibody drug conjugates 
can promote the death of malignant cells expressing the target antigen receptor as well as those 
nearby that lack the surface antigen through the bystander killing effects. 63 In contrast, non-
cleavable linkers are less likely to elicit bystander effects on unintended cells as the lysosomal 
degradation of the antibody carrier often yields polar metabolites unable to exit the cellular 
membrane.64 Radioimmunoconjugates are constructed and function in largely the same fashion as 
outlined for ADCs, with a couple of key differences. Firstly, the drug is substituted for a 
radionuclide, which is often in the form of a chelator which can bind with radioactive metal ions. 
In the case of radiolabeled antibodies, non-cleavable linkers are imperative and stability is 
paramount so that the radioactive payload is not released and remains antibody-bound. 
1.4.2. Immunoglobulin G (IgG). 
Immunoglobulin (IgG) proteins are the most abundant antibody species in human serum, 
with IgG1 as the dominant subclass.65 As such, most of the immunoconjugate research reported 
to date focuses on synthetic routes for modifying the IgG1 antibody framework to accommodate 
linker-bound therapeutic agents. These efforts concentrate heavily on the site-specific 
modification of nucleophilic lysine and cysteine side chains.66 67 While the IgG1 antibody hosts 
roughly 80 lysine residues, only a fraction of them lie within solvent-accessible domains. What’s 
more, the most accessible lysines are located on the protein’s CH2-domain, where lysine 
modification efforts can compromise the antibody’s antigen binding affinity.68 69 Cysteines, while 
less abundant, exist as sixteen accessible disulfide pairs on the IgG1 scaffold (Figure 1.6). This 
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lower number of potential binding sites decreases the number of potential isomers formed of the 
antibody conjugate; thereby reducing the antibody drug conjugate heterogeneity of cysteine 
relative to lysine overall.70 71 By reducing the heterogeneity of the product, the immunoconjugate 
compound elicits increasingly uniform pharmacological effects thereby improving its efficacy 
as a therapeutic agent. A caveat to this approach is that these disulfide-bridged cysteine residues 
are important structural components which hold large domains of the antibody together, and they 
must be reduced before bioconjugation of a payload can be performed. In contrast, lysine 
residues are not structurally integral and require no chemical modification before 
bioconjugation.  
 
Figure 1.6. Illustration of IgG1 antibody structure depicting 4 inter- and 12 intra-chain 
disulfide bonds. Constant and variable chain components are defined by letters (C) and (H) 
respectively. Light and heavy chains are denoted by subscripts (L) and (H) respectively. Figure 
adapted from those provided in (Garciarz, 2017; Absolute Antibody, accessed 2020; and Liu and 







































1.4.3. Disulfide Bridging Linkers. 
 While free cysteine residues can be engineered into the antibody sequence, native 
antibodies rarely host unpaired cysteines residues accessible for modification, but rather paired 
cysteines that bind to one another through oxidation and form disulfide bridges.75 76 77 These 
covalent bonds are essential to both the formation and maintenance of the protein’s tertiary 
structure, and subsequently their biological activity.78 79 Consequently, conjugation with most 
thiol-selective bioconjugation reagents result in the reaction of only a single cysteine residue, 
leading to disruption of the disulfide linkages and compromised structural integrity of the 
antibody.80 81 Disulfide rebridging linkers are designed to insert between paired cysteines and 
covalently bind to both thiol species to preserve the tertiary conformation of the protein.82 As two 
thiol-reactive moieties are required in disulfide rebridging bioconjugation reactions, the site-
specificity, and in turn, the product homogeneity of disulfide rebridging linkers is superior to that 







Figure 1.7. Illustrated reaction outcomes of antibody fragment subject to monosulfide-binding cysteine selective linkers and 
disulfide-bridging linkers demonstrating the differences in product heterogeneity. Figure adapted from (Nunes et al., 2015).84
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1.5. Cysteine Bioconjugation. 
Maleimide and maleimide derivatives are among the most frequently used non-cleavable 
linkers for cysteine residues; however, they could be considered to be “pseudo-cleavable” due to 
the inherent instability of the linkage and their propensity to undergo degradation via a retro-
Michael reaction. 85  86  The maleimide moiety undergoes the Michael addition reaction with 
thiolates, a common organic chemistry reaction, including cysteine thiolates found in antibodies. 
Maleimide acts as an electrophilic Michael acceptor for the thiolate nucleophile to attack and form 
a thioether adduct (Scheme 1.7).87 88  
 
Scheme 1.7. Michael addition reaction applying maleimide as a Michael acceptor for nucleophilic 
attack of cysteine residue’s thiolate moiety (R-S-); yielding thioether product. 
Maleimide and maleimide derivatives are extensively studied as both singular and 
rebridging cysteine linker variants. However, while maleimide is commonly applied by virtue of 
its specificity and fast reaction kinetics, the thiosuccinimide moiety is susceptible to in vivo retro-
Michael (β-elimination) degradation of the immunoconjugate and release of the maleimide 
rebridging agent and it’s attached payload from the antibody. What’s more, the newly liberated 
maleimide-payload complex can then interact with other biologically available thiols, cysteines, 
and glutathiones (Scheme 1.8).89 90 91 Consequently, the maleimide-linked immunoconjugates 
(drug or radionuclide) becomes a heterogeneous mixture of the antibody drug conjugate product 
and several by-products, which circulate through the blood stream leading to variable 
pharmacokinetics, therapeutic efficacy, and toxicity.92 93 These homogeneity issues observed of 
maleimide immunoconjugates have driven the research development of new linkers such as the 
promising phenyloxadiazolyl methyl sulfone (PODS) and its derivatives.94 
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Scheme 1.8. A) Bioconjugation of thiol-bearing biomolecule (green) and radionuclide-
bearing maleimide via Michael addition and subsequent hydrolysis to form a stable thioether. B) 
retro-Michael reaction of the bioconjugated product in the presence of thiol-bearing molecules 
from the biological environment such as glutathione (pink). Figure adapted from (Adumeau et al., 
2018).95 
1.5.1. Phenyloxadiazolyl Methyl Sulfone (PODS). 
 (Barbas et al., 2013) investigated the use of several methylsulfonyl‐functionalized 
heteroaromatic derivatives towards thiol conjugation based on the observed reactivity of 
methylsulfonyl benzothiazole (MSBT) blocking reagents. 96  They demonstrated selective 
nucleophilic aromatic substitution between phenyloxadiazole compounds and cysteine side-
chains. Reactions applying Barbas’ reagent took place at rates comparable to those applying 
maleimide and the resulting conjugates had comparatively superior stability (Scheme 1.9).97  




While this agent proved promising and caught the interest of several researchers, at some 
point during commercialization of the Barbas reagent errors must have been made as the 
commercial reagent had very low purity and, consequently, diminished use. After noting the 
commercial agent’s impurity issues and unwilling to denounce the compound’s promise, the 
research labs of Dr. Thomas Mindt and Dr. Brian Zeglis, in separate works, recently resynthesized 
the Barbas reagent.98 The Zeglis lab gave it the working acronym “PODS” and followed up on 
these efforts by incorporating the PODS functionality within the structure of two novel 
bifunctional chelators and successfully applying them towards the bioconjugation and 
radiolabeling of thiol- bearing biomolecules with [89Zr]Zr4+ and [177Lu]Lu3+.95 This work again 
demonstrated the vastly improved stability of the PODS linkage compared with maleimide and 
revived the underutilized PODS compound’s potential. 
 
Scheme 1.9. Reaction of the Barbas reagent with a thiol, forming stable conjugate product. 
Scheme adapted from (Toda et al., 2013).97 
1.6. Purpose Statement.  
With the growing number of radiochemistry applications comes opportunity to expand the 
toolbox of applicable radiotherapeutics and diagnostics. These efforts, including the synthesis of 
new and selective bimodal diagnostic agents, alternative radiolabeling methodologies, and 
improved radioimmunoconjugate stability were explored by the three projects presented in this 
thesis and outlined herein. 
The first project pertains to the imperative needs for diagnostic agents capable of localizing 
deep tissue bacterial infections. Compound of designation yellow (CDy11) is a BODIPY 
fluorophore that was previously found to selectively bind to the functional amyloids of the 
nosocomial pathogen Pseudomonas aeruginosa (PAO1). This project sought to improve the 
CDy11 dye’s diagnostic potential by applying Lewis acid-assisted 19F/18F-transfluorination 
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methods to the CDy11 precursor to synthesize a bimodal imaging agent applicable towards non-
invasive localization of P. aeruginosa infection and subsequent fluorescence-guided surgery. 
The second project outlined in this thesis tackles the challenge of the common SnCl4 Lewis 
acid agent commonly used to facilitate 19F/18F-isotopic exchange on the BODIPY core framework. 
The moisture-sensitive nature of SnCl4 results in the precipitation of tin hydroxide Sn(OH)4 and/or 
SnO2, which introduces variability to the overall reaction and can release HCl, potentially harming 
sensitive biomolecules or dyes. As such, the efficacy of hydrated magnesium nitrate Mg(NO3)2 
was explored as a mild and air-stable alternative to the conventionally applied SnCl4 for promoting 
19F/18F-transfluorination of a commercially available BODIPY dye. Furthermore, as the current 
literature lacks automated methods for the Lewis acid assisted [18F]-labeling of BODIPY dyes, 
efforts to automate the optimized procedures applying the stable hydrated Mg(NO3)2 salt solutions 
are outlined in an effort to provide reproducible and reliable BODIPY labeling strategies. 
Lastly, the third project discussed in this thesis outlines the synthesis of several of 
compounds involved in the multistep synthesis of the phenyloxadiazolyl methyl sulfone-based 
disulfide rebridging linker, DiPODS. These synthetic efforts were performed to assist in the 
production of the final DiPODS product as well as to investigate some intriguing observations 
made of the first synthetic product’s proton NMR. s the first product’s synthesis was believed to 
afford a mixture of rotamers, a series of variable temperature NMR experiments were performed 




Chapter 2 Preamble 
Chapter 2 describes the experimental efforts made towards radiolabelling compound of 
designation yellow (CDy11), a BODIPY dye found to selectively bind to the functional amyloids 
of the nosocomial pathogen Pseudomonas aeruginosa (PAO1), with [18F]-fluoride. The objective 
of this project was to produce 18F-radiolabeled CDy11 through Lewis acid-assisted 19F/18F-
transfluorination methodologies. Once labelled, the newly 18F-labeled dye was to be subjected to 
a series of ex vivo and in vivo analyses to determine its efficacy as a bimodal imaging agent for 
bacterial biofilms such as those found to develop in the moist environments of soils and bodily 
tissues. 
The CDy11 precursor was synthesized by collaborators (Dr. Michael Givskov and Dr. 
Liang Yang) and shipped to USask, but was repurified using HPLC instrumentation and confirmed 
using mass spectrometry.99 Success of the transfluorination experiments was evaluated through 
HPLC analysis using a system equipped with both UV-Vis- and radioactivity detectors. Although 
synthesis attempts of the desired [18F]F-CDy11product failed primarily because of the precursor’s 
instability, they illuminated inconsistencies in the jargon used to describe the Lewis-acid assisted 
radiofluorination methods, which require clarification. What is more, the moisture sensitivity of 
the Lewis acidic agent used in these reports, SnCl4, complicates the process as the amount of viable 
SnCl4 successfully introduced into the reaction medium is subject to a wide range of variability. 
The requirement of dispensing very small volumes of this reagent (~5-20  L) using a Hamilton 
microsyringe results in the production of visible HCl gas and white tin precipitate on the end of 
the needle, reducing the replicability of the reaction conditions and therefore yields. Ultimately, 
the decision was made to discontinue labeling attempts on the CDy11 BODIPY dye due to the 
molecule’s intrinsic instability, and instead turn focus towards improving the existing 19F/18F-
transfluorination methods by assessing the use of Lewis acids with no HCl liberation and improved 




2.1.1. Pseudomonas aeruginosa. 
The Pseudomonas aeruginosa (PAO1) bacillus is a biofilm-producing, Gram-negative 
pathogen found to live ubiquitously in nature, thriving in the moist environments of water, soils, 
and biological hosts. 100 101 102 The pathogenicity of PAO1 bacterium is a multifaceted composite 
of extracellular and structural aspects, resulting in a range of associated diseases.103 104 P O1’s 
infectious nature is further exacerbated by years of selective pressures that afford the bacteria 
recalcitrant, multi-drug resistance; rendering prevalently used antibiotics ineffectual.105 106 
2.1.1.1. Pseudomonas aeruginosa and Human Health. 
While rarely infecting healthy hosts, PAO1 is a common nosocomial pathogen found to 
frequently colonize clinical surfaces. Medical devices such as catheters,107 respiratory equipment, 
and pacemakers are all capable of enabling the infectious bacteria’s transfer to 
immunocompromised hosts;108 109 including patients suffering from various forms of cancer,110 
HIV and AIDs, 111  112  burn victims and respiratory diseases. 113  114  In particular, PAO1 is 
considered the leading cause of morbidity and fatality of cystic fibrosis patients.115 
2.1.2. Bacterial Biofilms. 
The superior resilience colonized PAO1 microbes exhibit towards environmental stress is 
attributed to their production of extracellular polymeric matrices otherwise referred to as 
“biofilms”. The biofilm is a complex and adaptive system of self-organized bacterial species 
primarily comprising of extracellular polysaccharides, extracellular DNA (eDNA), and proteins 
(Figure 2.1).116 117 
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Figure 2.1. A simplified structure of the biofilm composition. Figure adapted from 
(Flemming and Wingender, 2010; and Mani et al., 2018).116 117 
2.1.2.1. Advantages of the Biofilm System. 
The sessile lifestyle of biofilm-associated bacteria proves viably advantageous.118 The 
colonized bacterium exhibit van der Waals force that attract the prokaryotes towards one another, 
allowing them to adhere to both abiotic and biotic surfaces.119 These effects are enhanced by the 
bacteria’s envelopment within a self-secreted exopolysaccharide vesicle, enabling the associated 
bacilli greater opportunity to adhere with one another and the affected environment. 120  The 
formation of the biofilm encapsulant affords the amassed micro-community superior tolerance to 
the harsh conditions biocides and antibiotics may afford.121 
As the biofilm system matures, several physical and social properties emerge that offer the 
micro-community the means to sustain itself. The biofilm housed PAO1 bacteria display 
synergistic behavior with one another through social, metabolic and electrical interactions as well 
as their ability to capture and store nutritive materials.122 
2.1.3. Biofilm Associated Functional Amyloids. 
Pseudomonas-associated functional amyloids (Fap) are the principal proteinaceous 
constituent of PAO1 biofilms. 123  These insoluble fibrils extend from the bacteria’s outer 
membrane where they serve as adhesives allowing the cells to stick to one another and ultimately 
27 
colonize.124 125 The adherent fibers also act as protein-scaffolds in the developing matrix; helping 
to maintain the biofilm system’s structural integrity.126 
2.1.4. Compound of Designation Yellow 11 (CDy11). 
 A new BODIPY-based fluorescent probe was reported by (Kim et al., 2016).99 The novel 
biosensor, compound of designation yellow (CDy11) (Figure 2.2), was found to bind specifically 
to the Fap amyloids of Pseudomonas aeruginosa PAO1 biofilms. Initial in vivo assessments 
demonstrated CDy11’s potential as an optical imaging agent in thin tissue layers; emitting a 
fluorescence response at 576 nm when bound to the Pseudomonas-associated functional amyloids 
(Fap) biomarker. However, CDy11’s imaging abilities are limited by the effects of deep-tissue 
fluorescence attenuation and require further modification to fully realize its potential in the realm 
of clinical diagnostics. 
 
Figure 2.2. Chemical structure of CDy11. 
2.1.5. Purpose Statement. 
Resilient biofilm-associated bacterial infections, such as those caused by PAO1, require 
reliable selective diagnostic agents. This project aims to apply Lewis acidic [18F]-labeling methods 
to produce a radiotracer from the existing, biofilm-selective, CDy11 precursor. It is hypothesised 
that the optical and PET dual modality of the radiolabeled dye will expand CDy11’s diagnostic 
applicability beyond its limitations of fluorescence attenuation and allow for biofilm-associated 
bacterial infection localization at greater media depth.  
CDy11 will be subjected to Lewis acid facilitated 19F/18F-transfluorination and subsequent 
characterization using radioactive and UV/Vis HPLC. Following the confirmed synthesis of 
[18F]F-CDy11, the goal is to apply the isolated radiotracer in several ex vivo and in vivo 
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experimental models with the opportunistic PAO1 biofilms to assess the modified BODIPY dye’s 
performance as a selective bimodal indicator for the colonized Pseudomonas aeruginosa bacteria.  
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2.2. Experimental. 
2.2.1. Purification of CDy11. 
 The crude CDy11 precursor (0.050 g, 0.100 mmol) was received from our collaborators. 
Purifications and characterizations of the crude CDy11 compound were performed by applying 
HPLC-MS instrumentation using a Thermo Fisher Vanquish UHPLC system equipped with a 
Chromeleon 7 communication software, DIONEX UltiMate 3000 fraction collector, and C18 semi 
prep column (Spursil 5 μm C18, 250  21.2 mm reverse phase column, flow rate 8.00 mL/min). A 
similar system equipped with a reversed phase C18 UHPLC column with TMS endcapping 
(Luna® 5 µm C18(2) 100 Å, LC Column 250  4.60 mm, Ea, flow rate 0.50 mL/min) was used to 
assess radiofluorination of the CDy11 compound following experiments wherein differing 19F/18F-
isotopic exchange reaction conditions were applied. Gradient solvent systems of water: acetonitrile 
(95:5 to 5:95) and (70:30 to 5:95) with 0.1% formic acid were used for analysis and the methods 
were refined. Absorbance was measured at both 558 nm, the maximum absorbance of the CDy11 
precursor, and 254 nm, a common wavelength for aromatic compounds. 
2.2.2. CDy11 Radiofluorination. 
2.2.2.1. CDy11 Solution Preparation. 
CDy11 (1.10 mg, 2.25  10-3 mmol) was dissolved in a dry, sure seal vial using dry MeCN 
(1.10 mL) to afford a 1.00 mg/mL solution. 
2.2.2.2. Fluorine-18 ([18F]F-)-Production. 
 Fluorine-18 ([18F]F-) was produced by staff at the Saskatchewan Centre for Cyclotron 
Sciences (SCCS). [18O]O-H2O water was irradiated with high-energy protons using an ACSI TR24 
cyclotron. The primary batch of [18F]F- was used by the SCCS. Target-transfer lines were rinsed 
to obtain residual [18F]F- for facility user experiments; provided as an aqueous [18F]F- solution. 
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2.2.2.3. Azeotropic Drying of [18F]F- Solution. 
 The aqueous [18F]F- solution (~300 MBq) obtained from the SCCS was further diluted with 
deionized water (2.00 mL) and eluted through a potassium-carbonate ion exchange cartridge (Sep-
Pak QMA). The QMA trapped [18F]F- ions were subsequently eluted into a dry, sure-sealed 
overhead vial in the form of tetrabutylammonium [18F]F-fluoride ([18F]F-TBAF) by passing an 
ethanol-based solution of tetrabutylammonium bicarbonate (TBAB) (700 μL, 0.0 50 M) through 
the cartridge. The [18F]F-TBAF solution was azeotropically dried in the sure-sealed vial under a 
gentle stream of nitrogen gas by heating the vessel to 95 °C and adding MeCN (1.00 mL) to the 
existing solution. Solvent vapours were expelled from the vial through a vent needle as the process 
was repeated four times until a dry pale-yellow precipitate was visible along the inner walls of the 
vial (Figure 2.3). 
 
Figure 2.3. Illustration of the manual azeotropic dry down process. 
2.2.2.4. 19F/18F-Exchange of CDy11. 
Attempted radiosyntheses of [18F]F-CDy11 applied methods adopted from (Carlucci et al., 
2015; and Paulus et al., 2017).127 128 Azeotropically dried [18F]F-TBAF was reconstituted with 
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anhydrous acetonitrile (200 L). CDy11 was added to the solution and mixed for several minutes 
before addition of “catalytic” SnCl4 to assist in the exchange of CDy11-bound fluorine with the 
available [18F]F- ions in the reaction media. (Scheme 2.1). 
 
Scheme 2.1. Tin(IV) chloride (SnCl4) catalyzed, one-step radio-synthetic preparation of 
[18F]F-CDy11. The above reaction scheme uses TBAB to facilitate phase transfer of the reagents 
within the reaction media. 
Parameters such as reaction time, temperature, and reagent concentrations, underwent 
individual assessment to optimize the reaction conditions and achieve successful radiofluorination 
of the CDy11 dye.  
2.2.2.5. HPLC Analysis of CDy11 Post Reaction. 
The CDy11 reaction was quenched with deionized water (100 μL). The resulting solution 
was eluted through a C-18 SepPak and washed with deionized water (10.0 mL) to remove free 
[18F]F- ions from the sample. Organic components of the reaction mixture were eluted from the C-
18 cartridge using MeOH; collecting 100 μL fractions at a time. The activity of each fraction was 
measured using a dose calibrator. The MeOH-compound elutions found to contain the greatest 
amount of radioactivity were combined. A sample of the radioactive solution (25.0 μL) was loaded 
onto a Thermo Fisher Vanquish UHPLC system equipped with an Eckert Ziegler radioactivity 
detector through a 20 μL sample loop for analysis. It is noted that HPLC chromatography data was 
not obtained from crude samples, but rather the small amount of isolated samples as a proof of 
concept for 18F-labeling the Cdy11 molecule. 
32 
2.3. Results & Discussion. 
2.3.1. Purification of CDy11. 
 The crude CDy11 mixture was dissolved completely in acetonitrile before slowly adding 
H2O to make a solution with 3:8 solvent ratio respectively (2.04  10-3 M). The dark purple solution 
was sonicated and mixed with a vortex mixer several times before filtering with a 0.45 μm Promax 
PTFE filter. The resulting light red/pink solution was subjected to HPLC purification. 
 Mass spectrometry was used to confirm the CDy11 analyte’s isolation at 32.6 minutes 
within the HPLC chromatogram (Figure 2.4 and Figure 2.5 respectively). The purified CDy11 
was collected and presented as a clear vibrant fuchsia solution. Once collected, volatiles were 
removed via rotary evaporation and water was removed by freeze drying for 12 h before 
reconstituting with anhydrous acetonitrile (2.04  10-3 M). From this it was observed that of the 
original 0.0500 g of CDy11 dye provided, 7.00  10-3 g (15.9%) of the crude material was pure 
CDy11.  
A second HPLC injection of the purified compound was performed immediately following 
the initial purification to confirm isolation of CDy11 from the crude mixture. However, within 24 
h post purification, a third injection was performed prior to subjecting the CDy11 to [18F]-labeling 
conditions to serve as cold reference, showed degradation of the purified agent in the form of a 








Figure 2.4. HPLC chromatogram of crude CDy11 compound mix at 558 nm wavelength. HPLC purification was carried out 








Figure 2.6. HPLC chromatogram of the purified CDy11 compound 24 h, post purification. 




Figure 2.7. ESI+ Mass spectrum of reconstituted solution, post purification.
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2.3.2. CDy11 Radiofluorination. 
Prior to experimentation, several papers detailing BODIPY dye 19F/18F-isotopic exchange 
were studied to ascertain a grasp of the reaction procedure. The degree to which these articles and 
their supporting information described the radiofluorination procedures varied significantly. While 
some articles gave very few details, others had outlined a nucleophilic reaction with SnCl4 added 
to the BODIPY dye prior to introducing the [18F]F- solution into the reaction environment. A recent 
article had used the term “catalytic” when describing the use of SnCl4. Given the definition of a 
catalyst, this implies that the rate of 19F/18F-isotopic exchange is increased by the introducing the 
Lewis acid into the reaction mixture as it provides a more energetically favorable route for 
transfluorination to proceed. In addition to this, the catalytic agent should be regenerated, that is it 
should undergo no net change once it completes its assistance of the reaction. It is imperative to 
clarify that the SnCl4 reagent acts to abstract fluorine from the BODIPY core prior to the addition 
of the [18F]F- solution. In doing such, a reaction site is generated that allows for nucleophilic 
incorporation of a [18F]F- anion from the surrounding reaction media. That is to say, the Lewis acid 
must interact with the BODIPY precursor before incorporating the [18F]F- solution into the reaction 
medium. This abstraction process does not occur however without the formation of tin(II) and 
tin(IV) fluorides (SnF2 and SnF4) and the original SnCl4 reagent is not regenerated during the 
reaction. This misuse of the word “catalyst” deserves clarification as it introduces a source of 
discrepancy within the literature outlining the mechanism by which the Lewis acid assisted 
radiofluorination of BODIPY dyes is achieved. 
 The SnCl4 reagent’s moisture sensitivity is a potential source of variance for the reaction. 
The Lewis acid is drawn in very small quantities (~5-20 L) from a commercial sure-sealed vessel 
using a beveled Hamilton syringe. During the short period of time when the syringe is removed 
from the bottle to puncture the sure-seal capping of the reaction vial, tin(II) and (IV) oxides 
precipitate at the tip of the needle while HCl gas is liberated. Not only are these solids insoluble 
within the reaction environment, they also obstruct the remaining solution’s entry into the reaction 
vessel by either partially or fully clogging the needle. Both outcomes reduce the amount of Lewis 
acid available to facilitate the 19F/18F-transfluorination reaction to an unknown and unpredictable 
amount. While this variance may affect the reaction to a lesser degree for a larger scale reaction, 
radiofluorination processes are carried out on a small-scale level. In this case, with a milligram or 
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less of precursor used, the smallest deviance from the intended volume can have a significant 
impact on the molar equivalent of SnCl4 dispensed and therefore the reaction’s outcome, and the 
replicability of the experiment’s results. 
While degradation was found to occur within 24 h of purification, the CDy11 mixture was 
subjected to several variations of the radiolabelling procedures to radiolabel the remaining CDy11 
molecules within the sample. These attempts are outlined in Table 2.1. The success of the [18F]F-
CDy11 labeling attempts was assessed using HPLC analysis with both UV/Vis and radioactivity 
detectors. Given CDy11’s existing optical activity, the successful radiofluorination of the molecule 
affords new radioactivity-detector signal; the retention time (tR) of which corresponds with that 
observed of the fluorophore during UV-Vis HPLC analysis with a delay of ~0.7 min (radiation 
detector is placed after the UV-Vis detector in the flow-path). 
Despite the experimental attempts made, the Lewis-acidic conditions of the 19F/18F-
isotopic exchange reactions exasperated degradation of the CDy11 precursor. When comparing 
the UV-Vis chromatograms run of the unreacted CDy11 with reaction mixture, no CDy11 was 
found present post reaction. As such, while degradation products were labelled with [18F]F- anions 
during the attempted reactions, no [18F]F-CDy11 was observed in the radioactivity chromatograms 







Table 2.1. Summary of experimental parameters assessed during the attempted 18F-labeling of CDy11. Quantities (µg), solution 
volumes (µL), solution concentrations (µmol), and the number of equivalence values of reagents applied per experiment with respect to 
the BODIPY starting material (eq) are provided for each of the attempted labeling processes. Reaction duration is provided in minutes 
(min). The radioactivity associated with successfully 18F-labeled BODIPY is recorded for each of the outlined experimental efforts’ TLC 
and HPLC analyses as a percentage (%) of the total amount of BODIPY standard applied at the start of the reaction. The specific activity 
values obtained through TLC and HPLC analyses are reported as a measure of radioactivity (Mega Becquerel) per volume of the reaction 













1 50.0, 0.102 
TBAB 
261, 0.786 
268, 1.02 25 30 - - 
























3 50.0, 0.102 
TBAB 
13658, 45.0 
261, 1.00 50 30  - 










2.4. Conclusions & Future Directions. 
 CDy11 was obtained from our collaborator in low purity, with degradation of the re-
purified compound observed within 24 h. Subjecting the purified CDy11 product to Lewis-acidic 
19F/18F-isotopic exchange conditions seemingly accelerated the compound’s degradation, 
presumably due to the liberation of HCl from the SnCl4 reagent. Consequently, [
18F-]F-CDy11 was 
not produced under the applied reaction conditions.  
While the desired product could not be isolated, the use of moisture-sensitive agents such 
as SnCl4 presented as a notable source of variability for reaction’s outcome. Investigating the 
efficacy of water-stable Lewis acids towards facilitating 19F/18F-transfluorination at the BF2-
moiety of BODIPY fluorophores could offer alternative Lewis acidic agents for carrying out the 
reaction process with more consistent labeling yields. Follow up efforts exploring this notion are 
described in Chapter 3 of this thesis.  
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Chapter 3 Preamble 
 
Chapter 3 explores the use of an alternative Lewis acidic agent to facilitate 19F/18F-isotopic 
exchange at the BF2-moiety due to the variability the SnCl4 Lewis Acid introduces to the overall 
reaction process. To explore this idea, we selected a simple and commercially available BODIPY 
dye. As opposed to the moisture sensitive SnCl4 Lewis acid frequently applied in literature reported 
BODIPY 18F-labeling efforts, the following efforts describe the use of hydrated Mg(NO3)2 as a 
mild and stable alternative under the hypothesis that the agent will serve to effectively radiolabel 
the commercial precursor. The nitrate salt of magnesium was selected for maximum solubility so 
that a high-concentration stock solution could be prepared in water, and so that a minimum volume 
of water would be introduced into the radiochemistry reaction when transferring the solution. 
Efficacy of the 19F/18F-transfluorination conditions were evaluated using an HPLC system 
equipped with both UV-Vis-, radiation-detectors, and radio-TLC imaging scanner. While further 
experimentation is necessary to obtain an optimized 18F-labeling strategy applying hydrated 
Mg(NO3)2, initial efforts are reported and discussed herein. 
This chapter also outlines the efforts made towards automating the optimized Mg(NO3)2 
methods for radiofluorination of the commercial dye. Automation efforts were carried out an a 
Trasis miniAllInOne (miniAiO) synthesizer. While optimized methods remain under 
investigation, an automated method was established for the azeotropic drying and reconstitution 






3.1.1. Tin Chlorides. 
Of the reagents assessed by (Liu et al., 2013).53 during their original investigation into 
Lewis acid assisted [18F]F-BODIPY dye labeling strategies, Sn(IV) chloride afforded the most 
successful results. Consequently, the majority of efforts that have reported the use of Lewis acids 
to facilitate the 19F/18F-transfluorination of BODIPY-based imaging agents utilizes SnCl4 by 
convention. The Lewis acidic properties of tin(II) chloride and its milder counterpart tin(IV) 
chloride are commonly applied as catalysts. For example, on an industrial scale, tin chlorides often 
serve to promote the synthesis of polyester and Friedel-Crafts alkylation of aromatic rings.129 
3.1.1.1. Instability & Safety Associated with Tin Chlorides. 
Chloride salts of both the 2+ and 4+ oxidation states of tin have a wide degree of variability 
associated with their efficacy and pose health risks to personnel who come into contact with them. 
Both SnCl2 and SnCl4 are susceptible to hydrolysis in the presence of air and water; resulting in 
the loss of viable agent through the formation of tin hydroxide and/or oxide precipitates and HCl 
gas (Scheme 3.1). Thus, while tin chlorides can yield highly successful 19F/18F-transfluorination 
reactions for BODIPY dyes, the difficulty associated with handling them are a significant problem 




Scheme 3.1. Hydrolysis of: A) Sn(II) chloride and B) Sn(IV) chloride to produce Sn(II) 
and Sn(IV) precipitates respectively and HCl gas. C) Oxidation of Sn(IV) into insoluble Sn(IV) 
oxide and HCl gas. 
3.1.2. Magnesium Salts. 
Based on previous experiences where tin(IV) chloride was applied in the attempted 
radiofluorination of the BODIPY dye CDy11 (refer to Chapter 2), research objectives shifted 
towards investigating air-stable substitutes for the reactive Lewis acid. Although (Liu et al., 2013) 
had originally assessed the success of several Lewis acid alternatives, the scope of their analysis 
focused only on transition and post transition metals such as titanium and tin. By broadening our 
searches for an alternate Lewis acid beyond those previously studied, we noted that magnesium 
shares similarities with tin(II) and tin(IV). As shown in Table 3.1, the effective ionic radii of 
magnesium ions lies within a similar range to that of Sn(IV).130 131 132 What’s more, magnesium 
interacts with fluoride to form bonds of comparable strength (bond dissociation values) to those 
observed with tin; with (MgF)+ reacting with a second fluoride to form a bond with strength 
comparable to that forged between the anion and titanium; which (Liu et al., 2013) reported as the 
second most effective agent during their assessment.
 n     H O   n OH    H  
 n     H O   n OH    H  
 )
B)




Table 3.1. Energy of bond dissociation values reported for 298 Kelvin (D°298, kJ/mol) and effective ionic radii (pm) of relevant 













B-H 345 ± 3 131 Mg(II)-H2O 123 ± 13 131 Ti(IV) 60.5 132 
B-F 766 ± 13 130 Mg(II)-OH 314 ± 33 131 Sn(IV) 69.0 132 
BF-F 569 130 Mg-H 191 ± 6 131 Mg(II) 72.0 132 
Sn(IV)-F 476 ± 8 131 Mg(II)-F 477 ± 50 131 Ti(II) 86.0 132 






3.1.2.1. Magnesium Nitrate Hexahydrate [Mg(NO3)2]·6H2O. 
Magnesium nitrate [Mg(NO3)2] is a hygroscopic inorganic salt that forms its hydrated 
variant when exposed to water, or to air with sufficient moisture content. Although absorbing water 
modifies the Lewis acidic agent, magnesium is stable in its 2+ oxidation state and the hydrated 
species is stable and thus easily handled without posing risk of precipitation. Unlike tin and 
titanium chlorides, magnesium salts do not rapidly precipitate or liberate HCl. The additional water 
of the hydrated species would conventionally be of concern for radiochemists as the nucleophilic 
interactions between the water protons and [18F]F- anions  reduce the nucleophilicity of the fluoride 
and therefore the amount of radioactive isotope available for incorporation into the target 
compound. However, while 18F-fluorination reactions are normally performed in polar aprotic 
solvents, recent reports suggest that the presence of a small amount of water, even as a co-solvent 
may not always be detrimental to radiofluorination reactions.133  An example of a successful 
radiofluorination reaction that was performed under wet conditions is the production of ortho-
phosphonium aryltrifluoroborate zwitterions via nucleophilic 19F/18F-isotopic exchange; which 
was carried out by (Li et al., 2012) with water as the primary solvent and polar aprotic acetonitrile 
only present in trace amounts (Schemes 3.2).134 135 As such, the requirement to dissolve the 
magnesium salt into water and therefore the addition of a small quantity of water to the BODIPY 
radiofluorination reaction was not a deterrent.  
 
Scheme 3.2. 19F/18F-transfluorination of ortho-phosphonium aryltrifluoroborate 





3.1.3. Automated Radiosynthesis. 
The automation of synthetic procedures allows for the production (synthesis) of 
radiochemical agents to meet the standards of the good manufacturing processes (GMP) required 
for administering these agents within biological systems. Automation improves the replicability 
and reliability of radiolabeling methods by reducing the amount of human error that can in turn 
lead to variability between production batches and even production failure.136 This standardization 
has the added benefit of reducing the radiation exposure of production personnel, as the automation 
boxes can carry out a complicated radiosynthesis remotely or from behind lead shielding, using a 
series of valves, tubes, pumps, cartridges, and even in-line HPLC systems. While manual efforts 
require handling radioactive substances for extended periods of time and increased risk of 
contamination, the closed system of the automated synthesizer can be safely monitored from a 
distance via the instantaneous production feedback of the automation software. Finally, this lower 
exposure risk allows for the use of higher radioactivity levels during synthesis and, in accordance 
with the larger amount of radioactive isotope available for incorporation, higher radiochemical 
production yields and specific activity values for the reaction product.137 
3.1.3.1. Automated Synthesis Platforms. 
Currently, two of the leading automated systems used to produce GMP-grade 
radiodiagnostic agents are the GE TRACERlab FXFN and Trasis AIO (All in One) systems. Both 
synthesis modules have their benefits. As the TRACERlab FXFN was the first to arrive to market, 
it has since become the most widely applied system for automation of radiosynthetic procedures, 
with the most common example being [18F]F-FDG. Consequently, many of the automation and 
optimization strategies that have been published to date are in reference to the design and software 
of the TRACERlab system. However, because the system’s components that encounter reagents 
and radioactivity are fixed within the TR CERlab’s design, post-production cleaning steps require 
a further attention to assure GMP accreditation is maintained. However, the TRASIS AIO 
automated synthesizer is a cassette-based system that runs the reaction procedure through sterilized 
and commercially available disposable components. This design allows the user to modify the 
cassette to better suit the synthetic procedure being run on the system and dispose of the cassette 
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once synthesis is achieved, reducing the risk of cross contamination between production runs as 
well increasing the throughput of production. 138  
3.1.4. Purpose Statement. 
While the Lewis acid-based 18F-labeling strategies reported to date for BODIPY dyes 
afford high radiochemical yields, they are limited by the moisture sensitivity of the Lewis acidic 
agents applied to facilitate radiofluorination. Despite their described efficacy, the yields of the 
reactions applying tin and titanium as Lewis acids are subject to significant irregularity as their 
reactivity with water leads to varying amounts of reagent precipitation and the production of acidic 
fumes. Not only does this Lewis acid degradation prove problematic for manual labeling efforts 
as the precipitation results in reduced labeling yields and clogging of needles, reagent inlets, and 
outlets, but the deteriorative effects of the acidic fumes degradation on the synthesiser platform 
itself inhibit automation and GMP certification of BODIPY-based radiotracers altogether.  
As the original survey performed by (Liu et al., 2013) pertained to only a small range of 
applicable Lewis acids, there is room to improve the existing labeling strategies through assessing 
alternative Lewis acidic reagents. This project sought to explore the use of air-/shelf-stable Lewis 
acids with comparable chemical properties to those of Sn4+/Ti4+ as promoters for the 18F/19F-
isotopic exchange of BODIPY dyes. We hypothesized that magnesium(II) nitrate [Mg(NO3)2] 
could function effectively as 19F/18F-exchange promoting agent by virtue of its comparable acidic-
strengths and bond dissociation energies with those of tin and titanium ions. Furthermore, through 
our relationship with the Sylvia Fedoruk Centre for Nuclear Innovation, researchers are given the 
opportunity to gain familiarity with the TRASIS AIO synthesis platform. As such, the final goal 
of this project was to automate the optimized magnesium-based radiofluorination of a proof-of-
concept commercial BODIPY dye using the TRASIS AIO system to demonstrate the overall 




3.2.1. Mg(NO3)2·6H2O Solution Preparation. 
Concentrated solutions of Mg(NO3)2·6H2O were prepared by dissolving the hydrated salt 
(0.500 g, 1.95 mmol) in a minimal amount of solvent. Both polar protic and polar aprotic solutions 
of Mg(NO3)2·6H2O were made in this fashion and used for experimentation to assess the effects 
of solvent on the reaction yields (aqueous (polar protic) Lewis acid solutions were made using 
0.418 mL of deionized water for a final concentration of 4.66 M and polar protic solutions were 
made using 1.40 mL of DMSO for a Mg(NO3)2·6H2O  solution Molarity of 1.39 M). 
3.2.2. Tetraethylammonium Bicarbonate Solution Preparation. 
 Tetraethylammonium bicarbonate (71.7 mg, 0.375 mmol) was completely dissolved in 
deionized water (0.500 mL) and MeCN (4.50 mL), producing a freshly-made solution of phase 
transferring agent with 1:9 H2O:MeCN solvent composition for each 
18F-radiolabeling experiment. 
3.2.3. 19F/18F-Isotopic Exchange of BODIPY Dye Standard. 
3.2.3.1. [18F]F- Solution Production. 
 Aqueous [18F]F- anionic solutions were produced by staff at the Saskatchewan Centre for 
Cyclotron Sciences (SCCS) via a 18O(p, n)18F nuclear reaction using an ACSI TR24 cyclotron. 
The primary batch of fluoride-18 was used by the SCCS, and the target-transfer lines were rinsed 
to obtain residual [18F]F- ions for these experiments provide as aqueous [18F]F-. 
3.2.3.2. Manual Azeotropic Drying of [18F]F- Solution. 
 Aqueous [18F]F- (~300 MBq) obtained from the SCCS was diluted further with deionized 
water (2.00 mL) and eluted through a pre-conditioned Sep-Pak QMA cartridge. QMA trapped 
[18F]F- ions were subsequently eluted in the form of [18F-]F-TEAF by passing a freshly made 
solution of TEAB (700 μL, 0.0 50 M) through the cartridge. The [18F-]F-TEAF salt solution was 
azeotropically dried in a sure-sealed overhead vial immersed in an oil bath heated to 95 °C by 
adding MeCN (1.00 mL) and passing a constant stream of nitrogen gas through the vessel. Solvent 
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vapours were expelled from the vial through a vent needle. The azeotropic drying process was 
repeated four times and produced a dry pale-yellow precipitate along the inner walls of the vial. 
3.2.3.3. Automation Test for Azeotropic Dry Down and Subsequent Reconstitution of [18F]F--
Solution. 
 Using a small amount of activity for initial testing, aqueous [18F]F- (50-75 MBq) was 
transferred directly to the TRASIS MiniAIO automated synthesizer (Figure 3.1) through the 
activity inlet into the activity plunger. The synthesis module was operated in the following manner 




Figure 3.1. Diagram of the TRASIS MiniAIO automated synthesizer and cassette design used 
for the automated procedure. 
The following steps were programmed into the TRASIS MiniAIO system to automate the 




1. Aqueous [18F]F- (5.00 mL) was delivered to the TRASIS MiniAIO radiosynthesis module 
via the activity inlet. The aqueous [18F]F- ionic solution was eluted through the systems 
activity plunger and quantitatively trapped on a QMA carbonate ion exchange solid phase 
extraction (SPE) light cartridge (position 2). 
2. The resin-bound [18F]F- anions  were  eluted from the QMA cartridge with a solution of 
tetraethylammonium bicarbonate (TEAB) (0.0750 M, 4.00 mL) (position 4) in the form of 
[18F]F-tetraethylammonium fluoride ([18F]F-TEAF).  
3. The [18F]F-TEAF solution was transferred into the reactor vial (line positions 3→8→9) and 
dried azeotropically by addition of anhydrous acetonitrile (1.00 mL) (position 6) under 
reduced pressure at 95 °C. This process was repeated four times to afford [18F]F-TEAF as 
a dry, off-white/yellow solid lining the sides of the reactor vial. 
4. The reactor vial was cooled to 40 °C using a stream of nitrogen gas before addition of 
anhydrous acetonitrile (3.00 mL) (position 5) for reconstitution of the dried [18F]F-TEAF. 
The solution was transferring to a vented product vial.  
3.2.3.4.19F/18F-Isotopic Exchange Reaction. 
During several attempts to discern optimal reaction conditions through which magnesium 
nitrate could facilitate 19F/18F-transfluorination of a commercial BODIPY dye, various equivalents 
of magnesium nitrate hexahydrate and BODIPY dye standard were mixed at 37 °C for 5 minutes. 
Azeotropically dried [18F]F-TEAF was reconstituted with anhydrous acetonitrile (200 L) and 
added to the Lewis acidic mixture. Crude samples of the mixture were obtained as the reaction 
proceeded to assess the impact of time on the radiochemical yields obtained under the applied 
conditions. Reaction efficacy was assessed by subjecting the crude samples of the reaction mixture 




Scheme 3.3. General reaction scheme for 19F/18F-isotopic exchange of the commercial 
BODIPY standard using magnesium nitrate hexahydrate [Mg(NO3)2] as a Lewis acid to enable the 
reaction to proceed forward. 
3.2.3.5. HPLC Analysis of BODIPY Dye 18F-radiolabeling Condition Efficacy. 
A 20 μL-100 μL sample of the BODIPY standard solution was analysed using a 
ThermoFisher Vanquish UHPLC system equipped with a Chromeleon 7 communication software 
prior to each [18F]-labeling attempt. Samples were run via reverse-phase chromatography by 
applying a gradient solvent mixture of H2O: MeCN (70:30 to 5:95) with 0.1% formic acid. A C18 
HPLC column with TMS endcapping (Luna® 5 µm C18(2) 100 Å, LC Column 250  4.6 mm, Ea) 
was used for experimental analysis of the BODIPY standard. Absorbance was measured at both 
the absorbance maximum of the commercial dye of 505 nm, and 254 nm; a common wavelength 
for aromatic compounds. 
Crude samples of the reaction mixture were quenched with deionized water to afford a 
mixture of MeCN:H2O solvent ratio of 2:8. The sample mixture was filtered through a ProMax 
nylon syringe filter (pore size 0.2 µm, diameter 13 mm). The activity of a 20 μL sample subset 
was measured using a dose calibrator before loading the known volume onto a Thermo Fisher 
Vanquish UHPLC system equipped with an Eckert Ziegler radioactivity detector through a 20.0 
μL sample loop. Experimental analysis was performed using a reversed phase C18 HPLC column 
with TMS endcapping (Luna® 5 µm C18(2) 100 Å, LC Column 250  4.6 mm, Ea). Eckert Ziegler 
radioactivity detector was set at 2000 K sensitivity. Gradient solvent systems of H2O: MeCN 
(70:30 to 5:95) with 0.1% formic acid were applied during analysis. 
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3.2.3.6. Thin Layer Chromatography (TLC) Analysis of BODIPY Dye 18F-radiolabeling Condition 
Efficacy. 
 The efficacy of 18F-labeling attempts were evaluated via thin layer chromatography (TLC). 
The effects of reaction parameters such as time and reagent equivalents were assessed by spotting 
the crude reaction sample on three separate Fisher Scientific precoated aluminium-backed silica 
TLC plates. TLC strips were run using acetonitrile as an eluent. Crude yields were determined by 
analysing the TLC plates with a Bioscan AR-2000 radio-TLC plate reader using Winscan Radio-
TLC software (Bioscan Inc., Washington, DC).  
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3.3 Results & Discussion. 
3.3.1. Preparation of Mg(NO3)2·6H2O & TEAB Solutions. 
 Mg(NO3)2·6H2O and TEAB solutions were prepared as outlined in the 3.2 Experimental 
section. TEAB was selected as phase transfer agent to elute [18F]F- ions from the stationary phase 
of Sep-Pak QMA cartridges. The choice to use TEAB as an alternative for the TBAB previously 
employed during the 18F-fluorination attempts of CDy11 outlined in Chapter 2 was based primarily 
on their interchangeable use in literature. Cost efficiency also played a role in this decision as the 
TBAB sold by a single vendor was of GMP quality, which was not required at this stage of 
experimentation (998.00 $/5.00 g vs 222.00 $/25.0 g).139 140 
3.3.2. 19F/18F-Isotopic Exchange of BODIPY Dye Standard. 
 To assess magnesium nitrate hexahydrate’s efficacy towards facilitating 19F/18F-isotopic 
exchange on a commercial BODIPY dye, experimental procedures were first carried out applying 
SnCl4 as a Lewis acid. In doing such, reoptimized methods for the conventional Lewis acid were 
established as well as a general sense of the commercial dye’s reactivity. Based on these efforts, 
the BODIPY dye used for experimentation displayed minimal reactivity when subjected to 18F-
radiolabeling efforts; with optimal efforts producing a ~30% non-decay corrected yield when 
subjected to 50 equivalents of the SnCl4 Lewis acid for 30 minutes (Figures A1. and A2). The 
commercial BODIPY precursor’s minimal reactivity is attributed to the absence of electron 
withdrawing functionality within its molecular structure, which would afford inductive stability of 
the B-F bonds. While this increased inductive stability is not enough to hinder the breaking of B-
F bonds under the Lewis acidic conditions provided by mixing the dye with the Mg(NO3)2 solution, 
it is enough to better support their reformation when a surplus of fluoride anions, such as the [18F]F- 
solution, is introduced into the reaction medium.141 As was previously evaluated during 18F-
labeling attempts applying SnCl4, the order of reagents addition was assessed for experimental 
procedures utilizing the alternative Mg(NO3)2·H2O Lewis acid. The optimal order of addition did 
not change for reactions performed using the magnesium salt; the reaction did not proceed when 
the BODIPY and Lewis Acid were not combined prior to addition of the [18F]F- solution. 
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 Similar to experimental efforts with CDy11, several reaction parameters were assessed 
including the number of equivalents of applied reagents, reaction procession time, and the amount 















Table 3.2. Experimental parameters and TLC/HPLC results from 19F/18F-isotopic exchange attempts on commercial BODIPY 
dye. Quantities (µg), solution volumes (µL), solution concentrations (µmol), and the number of equivalence values of reagents applied 
per experiment with respect to the BODIPY starting material (eq) are provided for each of the attempted labeling processes. Reaction 
duration is provided in minutes (min). The radioactivity associated with successfully 18F-labeled BODIPY is recorded for each of the 
outlined experimental efforts’ TLC and HPLC analyses as a percentage (%) of the total amount of BODIPY standard applied at the start 
of the reaction. The molar activity values obtained through TLC and HPLC analyses are reported as a measure of radioactivity (Mega 
Becquerel) per volume of the reaction solution (MBq/ µmol). ctivity values listed in this table are non-decay corrected (NDC). The 







(eq, µL, µmol) 
Mg(NO3)2 
Lewis Acid 













1 200, 0.806 
55.8, 600 
(0.075 M), 45 
10, 1.73 (4.66 
M), 8.06 
*in H2O 
♦5 0.4 ± 0.2 0.5 
0.8 1.0 
15 0.3 ± 0 0.4 
30 2.2± 1.4 2.7 
45 1.6 ± 2.3 2.0 
2 200, 0.806 
55.8, 600 
(0.075 M), 45 
25, 4.32 (4.66 
M), 20.15 
*in H2O 
♦5 3.3 ± 0.3 4.0 
1.9 2.4 
15 1.6 ± 0.3 2.0 
30 2.9 ± 2.3 3.5 































3 200, 0.806 
55.8, 600 
(0.075 M), 45 
50, 8.65 (4.66 
M), 40.3 
*in H2O 
5 11.4 ± 0.2 14.1 
1.2 1.5 
15 6.6± 1.7 8.1 




4 200, 0.806 
55.8, 600 
(0.075 M), 45 
100, 17.3 (4.66 
M), 80.6 
*in H2O 
♦5 21.8 ± 1.4 27.1 
4.5 5.6 
15 19.3 ± 3.1 23.9 
30 22.0 ± 1.4 27.3 
45 30.2 ± 20.3 37.5 
5 200, 0.806 
55.8, 600 
(0.075 M), 45 
150, 26.0 (4.66 
M), 121 
*in H2O 
♦5 1.6 ± 0.4 2.01 
7.5 9.3 
15 22.6 ± 6.6 28.0 
30 25.4 ± 3.1 31.5 
45 23.7 ± 11.2 29.5 
6 400, 1.612 
27.9, 600 
(0.075 M), 45 
100, 34.6 (4.66 
M), 161.2 
*in H2O 
♦5 11.2 ± 6.7 6.96 
0.45 0.3 
15 16.0±0.1 9.92 
30 17.9 ± 3.3 11.1 












(eq, µL, µmol) 
Mg(NO3)2 
Lewis Acid 













7 200, 0.806 
75.0, 806 
(0.075 M), 60 
100, 17.3 (4.66 
M), 80.6 
*in H2O 
♦5 1.2 ± 0.6 1.45 
9.5 11.8 
15 2.2 ± 2.5 2.72 
30 0.4 ± 0.2 0.529 
45 1.5 ± 0.7 1.81 
8 200, 0.806 
55.8, 600 
(0.075 M), 45 
100, 58.0 (1.39 
M), 80.6 
*in DMSO 
♦5 1.2 ± 0.3 1.48 
8.3 10.3 
15 1.7 ± 1.2 2.15 
30 2.2 ± 1.3 2.76 
45 1.3 ± 1.0. 1.61 
9 200, 0.806 
55.8, 600 
(0.075 M), 45 
10, 1.73 (4.66 
M), 
*in H2O 
*15.6 µL extra 
H2O (total 
amount is the 
same as that 
added during 
100 eq runs) 
♦5 0.6 ± 0.5 0.707 
2.4 3.0 
15 0.9 ± 0.2 1.12 
30 0.7 ± 0.4 0.819 






To discern the best means for assessing the success of the BODIPY 19F/18F-
transfluorination procedures, both radio-TLC and radio-HPLC analysis were performed to varying 
degrees. All relevant spectra and chromatograms are reported in the Appendix section. Radio-TLC 
was primarily utilized as it was initially believed to provide a simple means of confirming the 
applied reaction conditions afforded labeling of the BODIPY precursor. Radio-HPLC analysis was 
performed as a secondary means of confirming reaction progress. However, based on the values 
provided in Table 3.2, clear discrepancies are noted between the radiochemical yields obtained 
via the two methods. Radio-HPLC analysis revealed an impurity peak, likely attributed to a 
hydrolyzed variant of the BODIPY molecule, in close proximity to that of the [18F]F-labeled 
commercial dye. Although HPLC affords resolution between the radiolabeled BODIPY product 
and the reaction impurity, the radio-TLC plate reader is unlikely to afford this refined distinction 
between the two. As such, the data obtained from the TLC reader is likely a composite of the two 
[18F]F-labeled compounds. This also offers explanation as to why the TLC data obtained over 
longer periods of time are significantly higher than those obtained for the same samples when 
analyzed with the HPLC system (entry 3 of Table 3.2). Technically, this reaction by-product was 
a radiofluorinated BODIPY dye and did indicate successful labeling, and the extent of 
decomposition into what was likely a hydrolyzed product would change depending on which 
BODIPY dye was being radiolabeled. As such, the presence of this impurity was not detrimental 
to the purpose of these experiments, which was to determine 1) if magnesium salts could facilitate 
this transfluorination reaction, and 2) what the optimum reaction conditions were. Future work 
would include applying these optimized methods to a variety of different BODIPY dyes.  
Based on the results obtained through HPLC analysis (Figure 3.2), use of 75 equivalents 
of the TEAB fixing agent relative to the molar amount of BODIPY dye precursor and 100 
equivalents of the magnesium nitrate hexahydrate salt dissolved in water afforded the highest 
radiochemical yields for the commercial BODIPY dye (entry 7 in Table 3.2). The large amount 
of excess Lewis acid required to facilitate 18F-radiolabeling of the BODIPY agent as well as the 
order of compound addition again supports the notion of the Lewis acid’s role as a reactant as 
opposed to serving as a regenerative catalyst. As the HPLC data lacks replicate analyses for 
statistical error and was not performed for each of the assessed parameter’s time points, further 
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investigative efforts must be performed in the future to improve the analysis of experimental 
results and isolate the desired 18F-labeled BODIPY product from the crude reaction mixture. 
 
Figure 3.2. Entry number ranking of radiochemical yields listed in Table 3.2 and obtained 
from the HPLC analysis of 19F/18F-isotopic exchange efforts on the commercial BODIPY dye from 
lowest yield to highest. 
Lewis acidic solutions of Mg(NO3)2 were prepared in both polar protic H2O and polar aprotic 
DMSO as solvents to assess the effects of water on the 19F/18F-transfluorination process. Upon 
comparison of the values reported for entries 4 and 8 of Table 3.2 wherein the only variable 
between these two reactions was the solvent used to dissolve the Mg(NO3)2 Lewis acidic agent, 
radio-HPLC analysis denoted nearly twice the radiolabeling yields from use of DMSO as solvent 
for the Lewis Acid solution. This suggests that water’s presence within the reaction medium 
followed convention of reducing the [18F]F--solution’s nucleophilicity in the reaction medium. 
This consequently resulted in lower radiochemical yields for the reactions carried out with aqueous 
Lewis acidic solutions than what could have been achieved using Mg(NO3)2 dissolved in polar 
aprotic DMSO. In accordance with this, while the reaction conditions outlined in entry 7 of Table 
3.2 afforded the highest radiochemical yields based on radio-HPLC chromatogram data and were 
carried out using an aqueous Lewis acid solution, this reaction was carried out using a greater 
equivalence of Mg(NO3)2. It is likely that, based on the results of entries 4 and 8 of Table 3.2, had 
a polar aprotic Lewis acid solution been used instead of the aqueous one, an even higher 
radiochemical yield of [18F]F-BODIPY would have been generated. As previously discussed, TLC 
chromatograms did not afford good resolution between the desired [18F]F-BODIPY product and 
radiolabeled hydrolyzed degradation product which offers an explanation as to why the TLC 
results reported for entry 4 are significantly greater than those of entry 8. Entry 9 of Table 3.2 
outlines efforts to further assess the effects of water on the reaction process by incorporating a 
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larger amount of water within the reaction but with the same molar equivalents of Mg(NO3)2 Lewis 
acid. While initially it may seem surprising that the radiochemical yield reported for the HPLC 
analysis of entry 9 is greater than that of entry 1 wherein the same amount of Lewis acid was 
applied, both yields remain low and the lack of replicate analyses performed with radio-HPLC 
instrumentation leave a wide window of variance wherein these values may fall. Consequently, a 
firm conclusion cannot be drawn at this time and further experimental evaluation is required to 
adequately evaluate the difference between these two reaction conditions. As general trends, when 
all other variables were kept constant, it appears as though increasing the equivalents of 
magnesium from 10-150 increased yields as indicated by entries 1-5 in Table 3.2. As discussed 
above, with all other variables kept constant, using DMSO as a solvent for the magnesium solution 
increased the yield relative to using water. Further, the quantity of base utilized (TEAB) had an 
impact on yields, where entries 5 and 8 in Table 3.2 show an increase in yields by increasing the 
quantity of base. In summary, more experiments are required to draw firm conclusions, but this 
work lays a good foundation to guide future experiments.   
3.3.3. Automation of Azeotropic Dry Down and Reconstitution of [18F]F-Solution. 
 Automation of the 18F-fluorination process’s azeotropic drying procedures presented 
several benefits. A major advantage of automating this procedure was that it provided a means for 
producing a bulk solution of the reconstituted [18F]F--solution in a short period with reproducible 
“dryness”. What’s more, due to the lower risk of radiation exposure associated with automating 
the process, a larger amount of radioactivity could be used during production, which would 
increase the amount of [18F]F- in the anionic solution available for incorporation in the BODIY 
18F-labeling experiments. This bulk solution could be split and used to assess several reaction 
conditions in a more-timely fashion. As the automated system eliminates human errors associated 
with timing and handling, the [18F]F--solutions prepared using the automated method would have 
less variance between them than those produced manually. Lastly, once the design of the 
disposable cassette and programmed method were established, minor adjustments of the existing 
protocol to incorporate the optimized BODIPY labeling strategies, as determined through manual 




To gain hands-on experience using the TRASIS miniAIO automated synthesis system and 
its operating software, a disposable cassette was designed for the automated dry down and 
reconstitution of [18F]F- in anhydrous acetonitrile. The reagents and consumables required as well 
as their position on the TRASIS cassettes depicted in Figure 3.1 are outlined below in Table 3.3. 
An automated method was established wherein an aqueous solution of [18F]F- was injected into 
the TRASIS system, trapped and released from a Sep-Pak QMA cartridge, azeotropically dried 
four times, and cooled before reconstituting the dried [18F]F-TEAF precipitate in 3.00 mL of dry 
acetonitrile and transferring the solution into a clean glass product vial. The commands for the 43-
minute-long method are provided in Appendix section. 
Once established, the method underwent trouble shooting to confirm that: 1) the [18F]F- 
trap and release process was able to elute all solution volume through the QMA into the reactor 
vial, 2) The [18F]F-TEAF salt was sufficiently dried under the applied conditions, and 3) that the 
product solution was properly transferred into the product vial. Initial tests were carried out using 
a small amount of activity (50-75 MBq) to monitor activity losses at various points during the 
automated procedure; namely the QMA cartridge and the reactor vial. After several test runs 
altering command times and nitrogen flow rates through the TRASIS system, the final test 
procedures for the azeotropic drying method afforded the desired [18F]F- solution with nearly 
negligible radioactivity losses in the cassette. 
Future efforts are required to finalize the automated 18F-radiolabeling process. The direct 
inlet of aqueous [18F]F- ions from the Fedoruk Centre’s ACSI TR24 cyclotron through the TRASIS 
system’s activity plunger attachment (position 2 in Figure 3.1) must still be assessed for the 
purpose of reducing user radioactivity exposure and handling. The [18F]F-TEAF solution produced 
using the automated method must still be applied under previously assessed conditions to validate 
the product solutions efficacy towards 18F-isotopic exchange. Lastly, the cassette will require 
further modification to incorporate the necessary reagents and intricacies of the optimized 




Table 3.3. Cassette composition and reagent loading for TRASIS MiniAlInOne synthesis module. 
Position Content/Connection 
Left End • Nitrogen Filter (0.20 µm) 
• Silicone Tubing (ID1mm, OD  mm) With Male Luer Lock- 1/16" Barbed Fitting ( 2) 
*Connecting System to Cassette Pressure Port 
1 • Silicone Tubing With Male Luer Lock- 1/16" Barbed Fitting 
*Connecting Activity Pump to System 
2 • QM  Carbonate Ion Exchange Solid Phase Extractions (SPE) Light 
• 20 mL BD Luer Lock Syringe (Exterior Only) 
•  ctivity Plunger With Direct Inlet from Cyclotron Line Rinse Run Through ctivity Inlet Pinch Valve 
3 • PE with 2 Connectors Luer Lock Male, overmolded (250 mm, ID1 mm, OD2 mm) 
*Connecting to Position 8 
4 • Nylon Luer Lock Ring: Square Hole 
• Spike: Polyacetal Male Luer Slip 
• Barrel for 1 mm Vial 
•  
18
F F- Fixing gent (TE B, 5 mL, 0.0 5 M) 
5 • Nylon Luer Lock Ring: Square Hole 
• Spike: Polyacetal Male Luer Slip 
• Barrel for 1  mm Vial 





   
Position Content/Connection 
6 • Nylon Luer Lock Ring: Square Hole 
• Spike: Polyacetal Male Luer Slip  
• Barrel for 1  mm Vial 
•  zeotropic Dry Down Solvent (MeCN   .8% nhydrous,   mL) 
Right End • Silicone Tubing With Female Luer Lock - 1/16" Barbed Fitting 
*Connecting to 20 mL BD Luer Lock Syringe 
Left End Empty 
7 • Silicone Tubing With Male Luer Lock- 1/16" Barbed Fitting ( 2) 




O collection Vial  
9 • Male Luer Lock- 1/16" Barbed Fitting 




Right End • Silicone Tubing With Female Luer Lock - 1/16" Barbed Fitting 
• 16 Gauge Needle (Connecting to Product Vial With Shielded Vent Needle Present) 
Reactor • Type 1 Glass Reactor-2 Tubes-8 Bar Validated Crimped Cap  
*Thin Tube Connecting to Position 9 via Male Luer Lock- 1/16" Barbed Fitting 





   
Specific Terms: 
• Activity Plunger: serves as the inlet for the radioactive solution produced by the Cyclotron into the TRASIS 
cassette setup. 
• Activity Inlet Pinch Valve: opens and closes to control the entry of radioactive solution from the cyclotron 
production into the automated synthesis cassette setup. 
• Barrel: holds consumable sure seal vial and contents in place on the TR SIS miniAIO automated 
radiosynthesizer cassette setup. 
• Spike: pierces sure seal septum of reagent to allow TR SIS mini IO system to access the reagent or solvent 






3.4. Conclusions & Future Directions. 
 It is clear the 19F/18F-isotopic exchange procedures outlined in this chapter require 
supplementary experiments to offer optimal reaction conditions for the commercial [18F]F-
BODIPY dye selected for this proof-of-concept study. Using Lewis acidic solutions made from 
the hydrated Mg(NO3)2 salt showed promising early results. Despite the need for further 
experimental investigation, several key aspects for future optimization and improved analysis of 
the radiolabelling conditions were emphasized. Despite recent reported successes of 18F-
fluorination efforts under wet conditions, the performance of 19F/18F-transfluorination for the 
commercial BODIPY precursor was improved under the conventional polar aprotic solvent 
conditions. As such, future experiments should employ concentrated Lewis acidic solutions made 
from DMSO solvent. Further, a general trend was observed that increasing the molar equivalents 
of magnesium (range of 10-150 equiv. tested) increased the radiochemical yield. It was also 
observed the quantity of base used (TEAB) influenced radiochemical yields. Although 
experimental analysis performed using a radio-TLC plate reader proves sufficient for many 
radiolabeling procedures, the degradation associated with hydrolysis of the BODIPY precursor 
and the availability of water under the applied reaction conditions makes TLC analysis an 
unfavorable means for evaluating the success of the applied experimental parameters. Instead, 
radio-HPLC analysis of the crude reaction mixture yields affords the necessary resolution for 
assessing the efficacy of the applied conditions and should be used going forward as the sole means 
for instrumental analysis of the 18F-labeling efforts performed on BODIPY fluorophores. 
 Attempts to devise an automated method for the 19F/18F-isotopic exchange of BODIPY 
dyes afforded hands on experience with building a functional cassette for the TRASIS miniAIO 
radiosynthesis platform, composing a method on the system’s associated operating software, and 
performing performance analyses of a new automated method and troubleshooting sources of error 
for the process overall. The initial azeotropic drying stage of the 18F-labeling process was 
successfully programmed and run through several rounds of error analysis. As such, it is ready for 
quality analysis of the [18F]F--solution product and further programming of optimized labeling 
conditions once methods are established.  
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Chapter 4 Preamble 
Chapter 4 outlines contributions made during collaborative efforts with Price lab 
postdoctoral fellow Dr. Elaheh Khozeimeh Sarbisheh to synthesize the novel disulfide-rebridging 
linker, double phenyloxadiazolyl methyl sulfone (DiPODS). Reported herein are the experimental 
procedures used to synthesize several of the compounds in the multistep synthesis of the final 
DiPODS linker. Syntheses of compounds 1-4 and 7 were confirmed with proton and carbon 
nuclear magnetic resonance (1H and 13C NMR) and high-resolution mass spectrometry. Peak 
assignments were supported by additional NMR experiments (DEPT135, HMQC, COSY). 
 While synthesizing compound 1 of the multistep procedure, curiosities peaked as the 
spectroscopic data associated with the crude product showed three signals with similar 1H NMR 
splitting patterns to that of the desired product. These extra proton signals were not discussed in 
the original literature outlining the compound’s synthesis.  dditionally, use of the crude mixture 
and its differing molecular species afforded quantitative yields in the subsequent synthesis step. 
As such, all three components afforded the same reaction product and therefore must have been 
isomers or derivatives of compound 1. It was thus hypothesized that the three sets of 1H NMR 
signals in the crude compound 1 mixture’s spectra were attributed to conformers or perhaps even 
rotamers of the compound 1 molecule. Detailed variable-temperature NMR and computational 
studies revealed this to be the case. 
In correspondence with this, Chapter 4 also outlines the use of spectroscopic techniques 
such variable temperature 1H NMR and FTIR spectroscopy to elucidate the structures of the 
compound 1 crude mixture components. In doing such, the major crude mixture components were 
characterized as a mixture of anti rotamers of the compound 1 product while spectroscopic data 
confirmed the minor constituents as doubly Boc-protected and imidic acid tautomer product 
variants. The efforts outlined within this chapter, in combination with those of Dr. Khozeimeh 
Sarbisheh and our collaborators in Dr. Zeglis’s lab, are summarized in a recently published 






Recent efforts in bioconjugation chemistry have acknowledged the imperative need to 
devise novel chemical linkers with improved in vivo stability. The recent success of our 
collaborators, (Zeglis et al., 2018),95 upon revisiting the applicability of the “PODS” functionality 
towards radioimmunoconjugate synthesis reaffirmed the potential of phenyloxadiazole-based 
bioconjugation reagents for covalently attaching a variety of chemical or radiochemical payloads 
to biological targeting vectors. However, as is the case with other thiol-reactive bioconjugation 
reagents that only react with a single cysteine residue, the disulfide bridges which maintain the 
antibody’s tertiary structure are broken. This lack of thiol rebridging reduces the stability of the 
antibody and increases the risk of fragmentation. 
In a joint effort to build off  the promising results of the PODS linkers, the Price and Zeglis 
labs sought to synthesize a novel disulfide-rebridging reagent, hereafter referred to as DiPODS. 
DiPODS (Scheme 4.1) contains two thiolate-reactive oxadiazolyl methyl sulfone moieties 
attached to the same aromatic ring system. It was hypothesized that this new DiPODS moiety 
would react with both cysteine residues from a reduced disulfide bond, affording doubly-












4.1.2. Isomers Hypothesis. 
 Synthesis of the DiPODS bioconjugation reagent was primarily carried out by Dr. Elaheh 
Khozeimeh Sarbisheh; a postdoctoral fellow of the Price lab group. As Dr. Khozeimeh Sarbisheh 
was establishing the multistep synthesis of the DiPODS product, she had noted that several of the 
intermediate products, most prominently compound 1, afforded a crude product mixture with some 
puzzling features. The spectra displayed multiple 1H nuclear magnetic resonance (1H NMR) peaks 
of similar splitting patterns and relative integration values to those of the desired product despite 
having subtly different shifts. In the case of compound 1, the major desired product could be 
separated from the crude mixture components by flash chromatography. To discern the presumed 
impurities’ effects on subsequent reaction yield for compound 2, Dr. Khozeimeh Sarbisheh 
proceeded with the second reaction while changing one key parameter. During one experiment, 
the reaction was performed using the crude product mixture and the second, she used an equivalent 
amount of the major product material that was isolated via flash chromatography (~40% of crude 
product). In doing such, she determined nearly quantitative conversion into compound 2, despite 
the presumption that the compound mixture contained possible impurities and thus, less of the 
actual compound 1. The consolidation of the previously described observations led us to 
hypothesize the crude product constituents, previously assumed to be reaction impurities, were 
conformational isomers of the desired products. More specifically, we hypothesized these 
chemical species could be rotational isomers (rotamers) of compound 1. 
4.1.2.1. Rotamers. 
Conformational isomers are the result of hindered rotation about a single σ-bond, 
producing a 3-dimensional variant of the molecular structure.143 Typically, a bulky functional 
group provides steric hindrance and thus hindered rotation. Rapid interconversion between 
conformers is possible when the required activation energy for conversion between conformers is 
small, allowing a mixture of conformers of varying ratios to exist at any given point in time when 
dissolved in solution. Conformational isomers typically interconvert at such a rapid pace they are 
indistinguishable from one another spectroscopically due a low energy barrier for rotation, thus 
free rotation about the sigma bond. A classic example of conformational isomerism is the rotation 
about the C-C bond of ethane (Figure 4.1). Because the eclipsed form of ethane experiences 
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greater Van der Waals repulsion between the adjacent C-H bonds compared to its staggered 
counterpart, it requires a higher energy input from the surrounding environment (i.e. thermal 
energy) to allow rotation about the C-C bond. However, they rapidly interconvert at room 
temperature as the required energy to facilitate rotation between the staggered and eclipsed ethane 
conformers is relatively small. These energy barriers are governed by several aspects of the 
molecular structure such steric repulsion and intramolecular hydrogen bonding.144 145 The more 
restricted the rotation about single bonds, the high the energy requirement; thus, rotational variants 
of the molecule, referred to as rotamers, are afforded. Rotamers preferentially adopt the 
conformation that is best accommodated/stabilized by the surrounding environment. That is to say, 
the most thermodynamically favourable rotamer/conformer is typically most abundant. The ratio 
of possible rotameric species within a given solution and, in correlation with this, the dominant 
rotamer can also be affected by conditions such as temperature and solvent properties (e.g. protic 




Figure 4.1. A) Eclipsed and staggered conformational variants of ethane molecule. B) Relative 
energy difference between staggered and eclipsed rotamers of ethane upon each 60° rotation about 
the molecule’s C-C bond. Figure adapted from (Mastering Organic Chemistry, accessed 2020).148 
4.1.3. Gibbs Free Energy & Conformational Stability. 
Gibbs free energy (ΔG) is a thermodynamic potential that is used to denote the minimum 
energy required for spontaneous conversion of reversible chemical processes at a constant 
pressure.149 150 Comparison of the Gibbs free energy values associated with each of the rotameric 
species hypothesized to exist in the compound 1 crude product allows for prediction of the 
compound 1 product’s thermodynamically favourable conformation. The Gibbs free energy 
associated with the conversion between rotamers of small molecules can be calculated by 
subtracting the product of the closed system’s change in entropy (ΔS) and the temperature (T) at 
which the process takes place from the change in enthalpy (ΔH) (Figure 4.2). This can be 
calculated from experimental data obtained using variable temperature 1H NMR, or it can be 





∆G = ∆H − T∆  
Figure 4.2. Gibbs free energy equation applicable for closed systems at constant pressure 
and temperature. 
4.1.3.1. Variable Temperature 1H NMR. 
1H NMR spectroscopy makes use of the naturally high abundance of the 1H isotope (99.9%) 
for elucidation of chemical structures. Each proton within a molecular framework can be thought 
of as hosting an individual charge. When the compound of interest is dissolved and placed into a 
magnetic field, proton nuclei will either align parallel with the surrounding field as a lower spin 
state (+1/2, spin up) or antiparallel to the external field as a higher spin state (-1/2, spin down).151 
Lower energy nuclei are promoted to the higher energetic spin-state by applying radiofrequency 
pulses. In doing such, the lower energy proton nuclei absorb different frequencies of the applied 
electromagnetic radiation based on their proximity to electron donating and withdrawing 
functional groups of the molecular structure that shield or deshield the nuclei from the applied 
radiation, respectively. Ultimately, these phenomena are detected by the NMR instrument, 
producing characteristic chemical shifts and signal patterns that enable characterization of the 
molecule’s structure features.152 
Variable temperature 1H NMR allows structural analysis of small molecules to take place 
as a dependent variable of the change in temperature over time. Subjecting rotameric species to 
changes in temperature promotes conformational adjustments as the molecule attempts to ascertain 
its most stable state. The rotation of functional groups about single bonds within the structure alters 
the proximity of their associated protons with those of the core structure. By changing the sample 
temperature in a controlled fashion and acquiring spectroscopic data at fixed intervals in time, the 
conformational changes associated with a mixture of rotamers can be monitored over time as they 
reconfigure their structure to achieve their most stable state. The values associated with each 
rotamer species’ changes in enthalpy, entropy, and Gibbs free energy are thus extrapolated from 
the experimental data obtained at each of the assessed temperatures. 
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4.1.4. Purpose Statement. 
 In a joint effort with Dr. Elaheh Khozeimeh Sarbisheh, this project sought to apply variable 
temperature 1H NMR spectroscopy instrumentation to monitor observed changes in chemical shift 
and concentration of the differing chemical constituents of the compound 1 crude product mixture.  
This data, in combination with the theoretical values calculated by Dr. Khozeimeh 
Sarbisheh using density functional theory (DFT), were used to assess our hypothesis that the three 
components of the compound 1 crude mixture were three differing rotameric species of the 
compound 1 material that, upon heating, would alter in conformation to yield the most stable 
rotamer. 
Furthermore, to assist Dr. Khozeimeh Sarbisheh in her production of the final DiPODS 
product as well as hone several organic synthesis techniques, compounds 1-4 and 7 from the 





4.2.1. Spectroscopic Characterization of Compounds 1-4 and 7. 
 Characterization of the synthesized compounds 1-4 and 7 was achieved using NMR 
spectroscopy. 1H, and 13C NMR spectra were recorded on a 500 MHz Bruker Avance NMR 
spectrometer at 25 °C in DMSO-d6. Variable Temperature 
1H NMR were recorded on a Bruker 
Avance III HD 600 MHz spectrometer. 1H chemical shifts were referenced to the residual protons 
of the deuterated DMSO-d6 and DMF-d7 solvents at δ = 2.50 ppm and 2.75 ppm respectively;
153 
13C chemical shifts were referenced to the DMSO-d6 signal at δ = 39.52 ppm.
154 Coupling constants 
are reported to the nearest 0.5 Hz (1H NMR spectroscopy) or rounded to integer values in Hz (13C 
NMR spectroscopy). Assignments were supported by additional NMR experiments (DEPT135, 
HMQC, COSY). High resolution mass spectra were measured on a JEOL AccuTOF GCv 4G using 
field desorption ionization (FDI). For the isotopic pattern only, the mass peak of the isotopologue 
or isotope with the highest natural abundance is given. FTIR spectroscopy was performed using a 
Bruker Tensor 27 FTIR spectrometer equipped with ATR attachment and OPUS data collection 
program. 
4.2.2. DiPODS Synthesis. 
4.2.2.1. Synthesis of 5-[[(1,1-dimethylethoxy)carbonyl]amino]-1,3-dimethyl ester (Compound 1). 
Compound 1 was synthesized following procedures outlined in (Y. Ohta et al., 2011).155 Using 
Schlenk techniques, dimethyl 5-aminoisophthalate (3.00 g, 14.34 mmol) and 4-
(dimethylamino)pyridine (2.24 g, 18.36 mmol) were purged with N2(g) and dissolved in anhydrous 
THF (50.0 mL). The clear yellow mixture was cooled to 0 °C prior to the addition of di-tert-butyl 
dicarbonate (4.00 mL, 17.50 mmol); upon which a thick, white precipitate formed inside the 
reaction vessel. The reaction mixture was kept under N2(g) flow as it initially stirred at 0 °C and 
gradually warmed to room temperature as the reaction proceeded over 24 h. Volatiles were 
removed by rotary evaporation before reconstituting the mixture with EtOAc (100 mL). The 
organic solution was washed twice with 0.5 N HCl (2×100 mL), three times with brine solution 
(3×100 mL), and deionized water (100 mL) to achieve a neutral pH. The organic layer was dried 
over Na2SO4 before removing the solvent under reduced pressure to yield the crude product 
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mixture as an off-white solid with negligible amounts of the Boc-deprotected starting material 
observed by 1H NMR (4.72 g, 106.4%) (Scheme 4.2). 1H NMR of the crude mixture (500 MHz, 
DMSO-d6, 25 °C, TMS): set A (anti-rotamers, anti-1) δ = 1.49 [s, 9H, NHCO2C(CH3)3], 3.88 [s, 
6H, CO2CH3], 8.08 (t, 1H, J= 1.43Hz, Ar-CH), 8.36 (m, 2H, Ar-CH), 9.89 (bs, 1H, NH) ppm; set 
B [doubly Boc-protected derivative of compound 1, (Boc)2-1]: δ = 1.39 {s, 18H, 
N[CO2C(CH3)3]2}, 3.90 [s, 6H, CO2CH3], 8.01 (d, 2H, J= 1.50Hz, Ar-CH), 8.41 (t, 1H, J= 1.50Hz, 
Ar-CH) ppm; set C (imidic acid tautomers of compound 1, tautomer-1): δ = 1.42 [s, 9H, 
NC(OH)OC(CH3)3], 3.91 [s, 6H, CO2CH3], 8.17 (d, 1H, J= 1.55Hz, Ar-CH), 8.45 (t, 2H, J= 
1.50Hz, Ar-CH) ppm; 13C{1H} NMR of the crude mixture (126 MHz, DMSO-d6, 25 °C, TMS): 
set A (anti-1): δ = 28.1 [NHCO2C(CH3)3], 52.5 [CO2CH3], 79.9 [NHCO2C(CH3)3], 122.5, 123.0 
(Ar-CH), 130.6 (Ar-C attached to CO2CH3), 140.7 [Ar-C attached to NHCO2C(CH3)3], 152.7 
[NHCO2C(CH3)3], 165.4 [CO2CH3] ppm; Signals associated with set B [(Boc)2-1], and set C 
(tautomer-1) of the crude mixture could not be distinguished from one another by 13C NMR 
techniques and are reported together herein. Crude mixture sets B and C: δ = 27.5, 27.5 
{N[CO2C(CH3)3]2} and [NC(OH)OC(CH3)3], 52.8, 52,8 [CO2CH3], 83.1, 84.4 {N[CO2C(CH3)3]2} 
and [NC(OH)OC(CH3)3], 128.3, 128.8 [Ar-CH], 131.0, 131.2 [Ar-C attached to CO2CH3], 133.0, 
133.1 [Ar-CH], 139.5, 140.0 [Ar-C attached to {N[CO2C(CH3)3]2} and NC(OH)OC(CH3)3], 150.6, 
150.8 {N[CO2C(CH3)3]2} and [NC(OH)OC(CH3)3], 164.7, 164.8 [(CO2CH3)2] ppm; HRMS 
(FDI): m/z calcd for C15H19NO6: 309.11977[M]
+; found: 309.11989; m/z calcd for 
C20H27NO8+Boc: 409.17815[M+Boc]
+; found: 409.17820; IR (FTIR): ṽ = 3364.40 (w) 
[NHCO2C(CH3)3, N-H], 2980.61 (w), 2954.57 (w) [{N[CO2C(CH3)3]2} & NC(OH)OC(CH3)3, C-
H], 2360.57 (w), 2339.30 (w) [NC(OH)OC(CH3)3, N=C], 1741.50 (m), 1726.07 (s), 1704.85 (s) 
[CO2CH3, C=O] 1604.57 (w), 1549.61 (m) cm
-1 [{N[CO2C(CH3)3]2}, C=O]. 
The first group of rotamers for compound 1 (set A, anti-1) was isolated from the crude mixture 
for further analysis via precipitation. The crude product (2.51 g, 8.12 mmol) was dissolved 
completely in a minimal amount of warm DCM and stored at -20 °C overnight. The set A crude 
mixture component was precipitated under the aforementioned storage conditions and were 
isolated from the mother liquor as a shiny white precipitate after vacuum filtration. The mother 
liquor was collected after vacuum filtration and subjected to rotary evaporation to remove solvent 
residues. The residual mother liquor solids were re-dissolved in minimal amounts of warm DCM 
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to repeat the precipitation process. Precipitation of  the set A mixture component was repeated 
several times until a pure product could no longer be isolated from the mother liquor solution (1.56 
g, 66.1%). 1H NMR of set A (500 MHz, DMSO-d6, 25 °C, TMS): δ = 1.49 [s, 9H, 
NHCO2C(CH3)3], 3.88 [s, 6H, CO2CH3], 8.08 (t, 1H, J= 1.45Hz, Ar-CH), .8.35 (d, 2H, J= 
0.851Hz, Ar-CH), 9.87 (bs, 1H, NH) ppm; 13C{1H} NMR of set A (126 MHz, DMSO-d6, 25 °C, 
TMS): δ =28.0 [NHCO2C(CH3)3], 52.5 [CO2CH3], 79.9 [NHCO2C(CH3)3], 122.4, 123.0 (Ar-CH), 
130.6 (Ar-C attached to CO2CH3), 140.6 [Ar-C attached to NHCO2C(CH3)3], 152.7 
[NHCO2C(CH3)3], 165.4 [CO2CH3] ppm; HRMS (FDI): m/z calcd for C15H19NO6: 309.11977[M]
+; 
found: 309.12124; IR (FTIR): ṽ = 3363.43 (m) [NHCO2C(CH3)3, N-H], 2952.65 (b) 




 Scheme 4.2. Synthesis of compound 1. 
4.2.2.2. Synthesis of Compound 2. 
 Hydrazine hydrate (28.0 mL, 451 mmol) was added to a clear colorless solution of 1 (3.49 
g, 11.28 mmol) in EtOH (150 mL) at room temperature. The color of the solution turned a pale-
yellow. The mixture was refluxed at 90 °C for 3 days. All volatiles were removed under reduced 
pressure to yield quantitative amounts of the product in the form of a fine, matte-white powder. 
The product material was used without further purification to proceed forward with the synthesis 
of compound 3 (3.49 g, quantitative yield) (Scheme 4.3). 1H NMR (500 MHz, DMSO-d6, 25 °C, 
TMS): δ = 1.48 [s, 9H, NHCO2C(CH3)3], 4.49 [bs, 4H, CONHNH2], 7.74 [t, 1H, J= 1.45Hz, Ar-
CH], 7.96 [d, 2H, J= 1.01Hz, Ar-CH], 9.64 [bs, 3H, NH] ppm; 13C{1H} NMR (126 MHz, DMSO-
d6, 25 °C, TMS): δ = 28.1 [NHCO2C(CH3)3], 79.5 [NHCO2C(CH3)3], 118.8, 119.6 [Ar-CH], 134.3 
[Ar-C attached to CONHNH2], 139.8 [Ar-C attached to NHCO2C(CH3)3], 152.8 
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[NHCO2C(CH3)3], 165.8 [CONHNH2] ppm; HRMS (FDI): m/z calcd for C13H19N5O4: 
309.14491[M]+; found: 309.14370. 
 
 Scheme 4.3. Synthesis of compound 2. 
4.2.2.3. Synthesis of Compound 3. 
 Potassium hydroxide (0.399 g, 7.11 mmol) was added to a suspension of 2 (1.00 g, 3.23 
mmol) in EtOH (34.5 mL) and stirred for 10 minutes. Carbon disulfide (4.30 mL, 71.1 mmol) was 
added in dropwise fashion to the stirring emulsion; turning the solution a vibrant yellow prior to 
the formation of a large amount of white precipitate. The reaction mixture was heated at 90 °C 
reflux overnight (16 h), during which time, the mixture became a clear pale-yellow solution with 
small amounts of white precipitate. After cooling the reaction solution to room temperature, EtOAc 
(320 mL) was added until complete dissolution of the precipitate material was achieved. The 
resulting clear yellow mixture was washed two times with 1 M HCl (2×320 mL) followed by 
washing 3 times with deionized water (3×320 mL) until neutral pH was achieved. The yellow 
organic layer was washed with brine (320 mL), then dried over Na2SO4 and filtered before 
removing volatile components under reduced pressure. Compound 3 was obtained as a shiny, 
lightweight white solid (0.704 g, 55.4% yield) (Scheme 4.4). 1H NMR (500 MHz, DMSO-d6, 25 
°C, TMS): δ = 1.51 [s, 9H, NHCO2C(CH3)3], 7.82 [t, 1H, J= 1.50Hz, Ar-CH], 8.22 [d, 2H, J= 
1.05Hz, Ar-CH], 10.05 [bs, 1H, NH], 14.75 [bs, 2H, SH] ppm; 13C{1H} NMR (126 MHz, DMSO-
d6, 25 °C, TMS): δ = 28.0 [NHCO2C(CH3)3], 80.3 [NHCO2C(CH3)3], 116.2, 117.5 [Ar-CH], 124.2 
[Ar-C attached to C2N2O], 141.5 [Ar-C attached to NHCO2C(CH3)3], 152.7 [NHCO2C(CH3)3], 
159.4 [C2N2O attached to Ar], 177.5 [C2N2O attached to SH] ppm; HRMS (FDI): m/z calcd for 
C15H15N5O4S2: 393.05703[M]





 Scheme 4.4. Synthesis of compound 3. 
4.2.2.4. Synthesis of Compound 4. 
 Triethylamine (3.39 mL, 24.2 mmol) was added to a clear yellow solution of Compound 3 
(2.63 g, 6.68 mmol) in dry THF (63.5 mL). After 10 minutes of stirring at room temperature, the 
color of the reaction mixture changed to a peach hue. To prevent light sensitive reagents from 
degrading, the reaction vessel was covered with aluminum foil. Iodomethane (1.11 mL, 17.8 
mmol) was slowly added to the reaction mixture and reacted for 3 h at room temperature. During 
the first 1-2 minutes of stirring, the clear peach solution quickly became opaque with white 
precipitate. Once the reaction was completed, the THF solvent was removed in vacuo to afford a 
mixture of white and tan colored solids. A crude form of the product material was extracted from 
the mixture with EtOAc (500 mL). The solution volume was reduced to 1/3 by evaporating 
volatiles under reduced pressure. This mixture was washed with a 0.1 M aqueous solution of 
Na2CO3 (2×100 mL); (pH=11). The deep-yellow organic phase was washed with brine (150 mL) 
and deionized water until a neutral pH was achieved. As the organic layer was neutralized, its 
coloring changed from deep yellow to a clear pale yellow. The organic phase was dried over 
Na2SO4 and filtered before removing solvent under reduced pressure. Product 4 was obtained as 
an off-white powder (2.61 g, 92.5% yield) (Scheme 4.5). 1H NMR (500 MHz, DMSO-d6, 25 °C, 
TMS): δ = 1.51 [s, 9H, NHCO2C(CH3)3], 2.79 [s, 6H, SCH3], 8.00 [t, 1H, J= 1.43Hz, Ar-CH], 
8.30 [m, 2H, Ar-CH], 9.99 [bs, 1H, NH] ppm; 13C{1H} NMR (126 MHz, DMSO-d6, 25 °C, TMS): 
δ = 14.4 [SCH3], 28.0 [NHCO2C(CH3)3], 80.2 [NHCO2C(CH3)3], 116.9, 117.7 [Ar-CH], 124.7 
[Ar-C attached to C2N2O], 141.5 [Ar-C attached to NHCO2C(CH3)3], 152.7 [NHCO2C(CH3)3], 
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164.2 [C2N2O attached to Ar], 165.3 [C2N2O attached to SCH3] ppm; HRMS (FDI): m/z calcd for 
C17H19N5O4S2: 421.08627[M]
+; found: 421.08784. 
 
 Scheme 4.5. Synthesis of compound 4. 
4.2.2.5. Synthesis of Compound 7. 
 Compound 4 (0.310 g, 0.712 mmol) was dissolved in a 1:1 mixture of TFA:DCM (8.0 mL). 
The mixture was stirred for 3 h at room temperature. The reaction solvent was removed under 
reduced pressure while the majority of TFA was removed azeotropically by washing the reaction 
mixture several times with toluene. The crude product was washed with a 5:2 mixture (20 mL) of 
MeCN: H2O and centrifuged at 4700 rpm for 9 minutes; yielding an off-white pellet and clear 
yellow solution. The pellet was washed twice with deionized water (2×20mL) and freeze-dried for 
24 h to afford compound 7 as a fine, off white powder (0.154 g, 67.2%) (Scheme 4.6). 1H NMR 
(500 MHz, DMSO-d6, 25 °C, TMS): δ = 2.77 [s, 6H, SCH3], 5.96 [bs, 2H, NH2], 7.36 [d, 1H, J= 
1.45Hz, Ar-CH], 7.56 [d, 2H, J= 1.38Hz, Ar-CH] ppm; 13C{1H} NMR (126 MHz, DMSO-d6, 25 
°C, TMS): δ = 14.3 [SCH3], 110.5, 113.5 [Ar-CH], 124.7 [Ar-C attached to C2N2O], 150.3 [Ar-C 
attached to NH2], 164.8 [C2N2O attached to Ar], 164.8 [C2N2O attached to SCH3] ppm; HRMS 
(FDI): m/z calcd for C12H11N5O2S2: 321.03545[M]
+; found: 321.03542. 
 
 Scheme 4.6. Synthesis of compound 7. 
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4.2.3. Variable Temperature 1H NMR Spectroscopic Analysis of Compound 1 Isomeric Forms. 
Two NMR samples were prepared in 5 mm Wilmad High throughput borosilicate NMR 
tubes. As previously described, compound 1 contained a mixture of components, which were 
partially separated by successive precipitation from a cold mother liquor solution. From this, two 
samples were made: 1) a solid precipitate of set A (anti-rotamers of compound 1, anti-1) (5.21 mg, 
1.68  10-2 mmol) 2) the vacuum-dried remains of the mother liquor solution; a 1.0:1.4:1.6 ratio 
of set A: set B: set C [anti-1, (Boc)2-1, tautomer-1] (5.32 mg, 1.72 10 
-2 mmol). Both samples 
were dissolved in DMF-d7 (0.401 mL and 0.409 mL respectively) immediately before subjecting 
them to 1H NMR analysis at 25 °C (298.15 K) on a Bruker Avance III HD 600 MHz spectrometer; 
with 16 scans run every 10 minutes for 1 h. Once the last data point was obtained for the samples 
at 25 °C (298.15 K), sample temperatures were increased to 75 °C (348.15 K) and stabilized for 
10 minutes before re-tuning, re-shimming and re-locking the system onto the deuterated solvent 
signal for acquisition of 1H NMR data every 10 minutes for 1 h. These processes were repeated to 
collect 1H NMR data sets for these two NMR samples at temperatures of 80 °C (353.15 K), 85 °C 
(358.15 K), and 90 °C (363.15 K) before rapidly cooling the samples with liquid nitrogen for data 
collection at -40 °C (233.15 K). The experimental process was repeated as described with new 
samples of the product mixture and the isolated anti-rotamers of compound 1 in DMSO-d6 with 
the exception of data collection at -40 °C (233.15 K). 
Calculations implementing the experimental data were based on the integrated values of 
the peaks located in the designated regions of the 1H NMR spectra. For experiments carried out in 
DMF-d7 solvent at room temperature, integration values of peaks located at 7.77 (m, 1H, Ar-CH), 
8.51 (t, 1H, J=1.53 Hz, Ar-CH), 8.53 (d, 2H, J=1.26 Hz, Ar-CH), and 8.55 (t, 1H, J=1.53 Hz, Ar-
CH) ppm were used for assessing the proportions of the Boc-deprotected derivative of compound 
1, set B [doubly-protected derivative of compound 1, (Boc)2-1], set A (anti-rotamers of compound 
1, anti-1), and set C (imidic acid tautomers of compound 1, tautomer-1), respectively. As 
subjecting the crude 1H NMR sample to elevated temperatures resulted in peak shifts within the 
spectra, the integration values of peaks located at 7.78 (t, 1H, J=1.54 Hz, Ar-CH), 8.47 (d, 2H, 
J=1.52 Hz, Ar-CH), 8.50 (t, 1H, J=1.53 Hz, Ar-CH), and 8.54 (t, 1H, J=1.54 Hz, Ar-CH) ppm 
were used for assessing the proportions of the Boc-deprotected derivative of compound 1, set A 
(anti-rotamers of compound 1, anti-1), set B [doubly Boc-protected derivative of compound 1 
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(Boc)2-1], and set C (imidic acid tautomers of compound 1, tautomer-1), respectively for the 
remaining data sets. The formation of a fourth set of 1H NMR peaks  (set D, syn-rotamers of 
compound 1, syn-1) was observed upon heating to 90 °C in DMF-d7, however the data for set D 
in DMF-d7 was not assessed as the signals overlapped with those of the set A anti-1 signals. 
Similarly, for experiments carried out in DMSO-d6 solvent at room temperature, the 
integration values of peaks located at 8.09 (t, 1H, J=1.43 Hz, Ar-CH), 8.41 (t, 1H, J=1.43 Hz, Ar-
CH), and 8.45 (t, 1H, J=2.95 Hz, Ar-CH) ppm were used for assessing the proportions of the set 
A (anti-rotamers of compound 1, anti-1), set B [doubly Boc-protected derivative of compound 1, 
(Boc)2-1], and set C (imidic acid tautomers of compound 1, tautomer-1), respectively. Integration 
values of peaks located at 7.88 (t, 1H, J=1.47 Hz, Ar-CH), 8.10 (t, 1H, J=1.50 Hz, Ar-CH), 8.14 
(t, 1H, J=1.47 Hz, Ar-CH), 8.42 (t, 1H, J=1.50 Hz, Ar-CH), and 8.46 (t, 1H, J=2.82 Hz, Ar-CH) 
ppm were used for assessing the NMR percentage of the Boc-deprotected derivative of compound 
1, set A (anti-rotamers of compound 1, anti-1), set D (syn-rotamers of compound 1, syn-1), set B 
[doubly Boc-protected derivative of compound 1, (Boc)2-1], and set C (tautomers of compound 1, 




Figure 4.3. A) Structures of each component discovered in the compound 1 mixture and 
the corresponding 1H NMR spectra in DMSO-d6 of the aromatic region of:B) the crude mixture 
before precipitation or column chromatography. C) The isolated precipitate from cold DCM. D) 
The final mother liquor containing a mixture of all 3 components at 25 °C.and E) The final mother 
liquor mixture at 90 °C. Peaks associated with the anti-rotamers of compound 1 (anti-1, set A, ), 
a doubly Boc-protected derivative of compound 1 [(Boc)2-1, set B, §], an imidic acid tautomer of 
compound 1 (tautomer-1, set C, ■), and syn-rotamers of compound 1 (syn-1, set D, ▲) are 
designated by the symbols , §, ■, and ▲, respectively. For simplicity, only one conformer of 








4.3. Results & Discussion. 
4.3.1. Multistep Synthesis of DiPODS. 
 Compounds 1-4 and compound 7 were synthesized via procedures established by (Y. Ohta 
et al., 2011) and (Khozeimeh Sarbisheh et al.; 2020).155 142 The success of these synthetic efforts 
was confirmed for each compound using a myriad of spectroscopic techniques; the spectra of 
which are provided in the appendix section of this dissertation. These newly synthesized 
compounds were intermediates of the multistep synthetic procedure utilized to produce the desired 
DiPODS end product. Ultimately, Dr. Khozeimeh Sarbisheh was able to successfully produce the 
DiPODS product, which has since been sent to our collaborators and assessed in terms of its 
stability and applicability as a disulfide-rebridging reagent. This work was recently published as a 
peer-reviewed manuscript in the American Chemical Society journal Bioconjugate Chemistry. 
4.3.2. Precipitation of Compound 1 in Attempt to Isolate Rotamers. 
 The number and splitting pattens for the peaks that presented in the aromatic region of 
compound 1’s crude product 1H NMR spectrum were hypothesized to result from two symmetric 
and two asymmetric conformers (Scheme 4.7). As three distinct sets of proton signals were 
observed, it was believed that two of these signals were attributed to symmetric rotational isomers 
(A and B of Scheme 4.7) while the third set was presumed to be a mixture of the asymmetric 
product variants (C and D of Scheme 4.7). Assessing this hypothesis began with attempts to isolate 
the product conformers from one another via precipitation with the objective of recrystalizing the 




Scheme 4.7. Synthesis of compound 1 illustrating the hypothesized symmetric products A 
and B, and asymmetric products C and D. 
A mother liquor of compound 1 crude product was subjected to six sequential precipitation 
attempts and afforded isolation of the major mixture component as shown by the decreasing 
intensity of the peaks associated with component set A in the 1H NMR spectra of the dried mother 
liquor after each Figures 4.3. Yields associated with each round of precipitation are provided in 
Table 4.1. While the first two rounds of precipitation afforded a shiny needle-like precipitate of 
the mixture’s primary component, further rounds of precipitation from the mother liquor afforded 
mixture of all three mixture constituents (Figure 4.4). 
As both minor mixture components precipitated out of the mother liquor at the same time, 
they were not isolated from the solution. TLC analysis was used to assess the efficacy of different 
solvents and solvent ratios towards separating the minor mixture constituents from one another but 
proved unsuccessful. Furthermore, although attempts to recrystalize the isolated major mixture 
component were made using different solvents, solvent mixture ratios and temperatures, crystals 
of X-Ray crystallography quality were not obtained. Thus, further efforts to assess the compound 
1 product mixture components focused on the use of spectroscopic instrumentation and DFT 
































Symmetric Products A & B






 Table 4.1. Precipitate yields for each isolation process. 
Sample Yield (g, %) Mother Liquor (mL) Mother Liquor (g) 
Crude product 2.51, 100 5.00 - 
Crystallization 1 0.796, 33.7 4.00 - 
Crystallization 2 0.540, 22.9 2.50 - 

















Figure 4.4. Stacked 1H NMR spectra of compound 1 crude mixture and the resulting mother liquor obtained from repeated 
precipitation processes. Peaks associated with compound 1 mixture components are distinguished from one another with labels for set 
A (anti-rotamer, anti-1, ), set B [doubly Boc-protected derivative of compound 1, (Boc)2-1, §], and set C (imidic acid tautomer of 
compound 1, tautomer-1, ■).
Crude Mixture of  Compound 1
Mother Liquor After Precipitation Round 3
Mother Liquor After Precipitation Round 4
Mother Liquor After Precipitation Round 5







































Figure 4.5. Stacked 1H NMR spectra of compound 1 crude mixture and isolated mixture components obtained through repeated 
precipitation. Peaks associated with compound 1 mixture components are distinguished from one another with labels for set A (anti-
rotamer, anti-1, ) , set B [doubly Boc-protected derivative of compound 1, (Boc)2-1, §] , and set C (imidic acid tautomer of compound 
1, tautomer-1, ■) . Spectra were obtained when from samples dissolved in DMSO-d6 solvent. 
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4.3.3. Variable Temperature Analysis of Compound 1. 
Variable temperature 1H NMR experiments were performed on samples of both the 
compound 1 crude product mixture and the isolated major mixture component, modeling 
experimental procedures outlined by (Humbert et al., 2014).156 The experiments were performed 
in polar aprotic solvents. Deuterated DMSO was originally used for experimental data collection. 
This was mirrored when Dr. Khozeimeh Sarbisheh established the DFT theoretical modeling of 
the conformational changes and their associated energies as she populated the surrounding 
environment of the model with DMSO as solvent. Deuterated DMF was used during follow up 
experiments given its comparatively lower freezing point (18 °C vs -61 °C), which enabled 
assessment of the compound 1 product mixture when subjected to low temperatures.157 
As temperature was adjusted over time, signal intensity changes in the aromatic region of 
the compound 1 product mixture’s 1H NMR were monitored. Figures 4.6 and 4.7 depict the 
aromatic regions of 1H NMR spectra obtained during analysis of the compound 1 mixture for 
various temperatures at which data was collected in DMSO-d6 and DMF-d7 respectively. While 
the signals associated with aromatic framework’s protons exhibited minor shifts upon the initial 
increase in temperature from 25 °C to 75 °C, the carbamate (N-H) peak of the major mixture 
constituent (set A) was found to move further upfield with every increase in temperature. This 
upfield shift suggests the carbamate functionality undergoes a rotational change that increases the 
amount of electron shielding experienced by the N-H proton at higher temperatures. Subsequent 
cooling of the heated sample, as performed during experiments carried out in DMF-d7, caused the 
N-H peak to reposition itself downfield; further signifying the temperature dependent change in 
conformation about the molecule’s N-C bond. Increases in temperature resulted in the formation 
of compound 1 degradation products such as the Boc-deprotected agent and isobutylene. In 
addition to this, increasing temperatures afforded a new set of peaks (set D) that were visible within 
the 1H NMR spectra of the product mixture obtained in DMSO-d6. The absence of this set of peaks, 
believed to result from a new set of conformers taking form under these conditions, from the DMF-
d7 spectra is likely due to overlap with larger peaks that mask their presence. Lack of peak splitting 
during variable temperature 1H NMR analysis discredited the notion of peak overlap as an 
explanation for the higher integration values of one of the molecules’ tert-butyl functional groups, 
thus supporting the notion that the second set of peaks within the 1H NMR spectra (set B) resulted 
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from the presence of a doubly Boc-protected variant of the product. This information offered 
sufficient explanation as to why the second set of peaks lacked a signal indicative of a secondary 
amine proton (carbamate, Boc-protected amine) as incorporation of a second tert-butyl carbamate 
functionality within the molecular structure was via substitution of the N-H proton; forming a 
doubly Boc-protected tertiary amine.  
While these observations proved helpful towards the understanding of the goings on within 
the compound 1 mixture at elevated reaction temperature, they did not afford any further 
explanation towards the absence of a N-H proton signal for the remaining minor mixture 
constituent (1H NMR peak set C). As such, further analysis of the compound 1 mixture was 
performed by implementing FTIR spectroscopy. By comparing the FTIR spectra of the product 
mixture (Figure 4.8) with that of the isolated major constituent (Figure 4.9) it became clear that 
the three original sets of proton signals previously hypothesized to be different conformers of the 
product molecule were instead the product material (set A), a doubly Boc-protected derivative of 
the compound 1 molecule (set B) and imidic acid tautomers of compound 1 (set C). The presence 
of imidic acid tautomers is primarily supported by the solid compound 1 mixture sample producing 
an additional FTIR signal at 2339.30 cm-1 indicative of a carbon-nitrogen double bond (N=C). 
While a literature reference supporting this aromatic ring-bound carbon-nitrongen double bond 
could not be found,  the approximate value of the imidic acid tautomer is supported by 
computational calculations for the theoretical FTIR spectral analysis performed by Dr. Khozeimeh 
Sarbisheh.142 
Further comparisons between the experimental results and the computational models 
performed by Dr. Khozeimeh Sarbisheh suggest that the 1H NMR signals collectively identified 
as peak set Aare attributed to several anti-rotamers of the compound 1 product with respect to the 
priority assignment of the functional groups bound to the structure’s N-C bond. These 
conformational isomers are believed to reside within a relatively similar energy domain and as 
such, present as a single set of peaks within the 1H NMR spectra due to rapid rotational 
interchangeability occurring within the timescale of the instrument’s acquisition period. As 
previously mentioned, heating the product mixture sample dissolved in DMSO-d6 solvent afforded 
a fourth set of peaks (set D). This fourth set of peaks is believed to indicate the formation of syn-
rotameric variants of compound 1 with respect to the priority assignment of functional groups 
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about the molecule’s N-C bond which, based on the DFT models performed by Dr. Khozeimeh 
Sarbisheh, require greater energy input from the surrounding  to ascertain this conformation and 
are therefore a less favourable conformation. The formation of less favourable syn-1 rotamers has 
been previously reported by both (Moraczewski et al. 1998) and Marcovici-Mizrahi et al., 
1996).158 159 The formation of the syn-compound 1 rotamers (peak set D) was not observed in the 
experimental data obtained using the isolated anti-conformers of compound 1, their formation in 
this case cannot be attributed to temperature-facilitated rotation about the N-C bond of the anti-
compound but rather must result from the structural changes of the minor mixture constituents i.e. 
the doubly Boc-protected and imidic acid product 1 tautomers. However, from the experimental 
data ascertained, it cannot be determined which if not both of these mixture components afford the 




Figure 4.6. 1H NMR spectrum of the compound 1 product mixture in DMSO-d6 solvent at 25 °C to 90 °C. Peaks associated with 
the anti-rotamers of compound 1 (anti-1, set A), a doubly Boc-protected derivative of compound 1 [(Boc)2-1, set B), an imidic acid 
tautomers of compound 1 (tautomer-1, set C), syn-rotamers of compound 1 (syn-1, set D), and the deprotected derivative of compound 
1 are designated by the symbols , §, ■, ▲, and ӿ, respectively. Peaks associated with dichloromethane are denoted by the symbol +. 






     
 Figure 4.7. 1H NMR spectrum of the compound 1 product mixture in DMF-d7 solvent at 25 °C to 90 °C. Peaks associated with 
the anti-rotamers of compound 1 (anti-1, set A), a doubly Boc-protected derivative of compound 1 [(Boc)2-1, set B), an imidic acid 
tautomers of compound 1 (tautomer-1, set C), and the deprotected derivative of compound 1 are designated by the symbols , §, ■, and 



























































Figure 4.8. FTIR spectrum of compound 1 product mixture from the final mother liquor of successive precipitations (mixture 
of set A, B, and C), including the anti-rotamers of compound 1 (anti-1, set A), a doubly Boc-protected derivative of compound 1 
[(Boc)2-1, set B), and an imidic acid tautomers of compound 1 (tautomer-1, set C). Additional signals were observed in the ~1704-1742 
cm-1 range when compared with the anti-rotamers of compound 1 (anti-1, set A) (Figure 4.9), which are likely arising from the additional 






































Figure 4.9. FTIR spectrum of the anti-rotamers of compound 1 (anti-1, set A) isolated as a precipitate from cold DCM. Figure 







As the sample mixture was no longer believed to contain isolated rotameric species of the 
product molecule, the Gibb’s free energy calculations that were originally intended to result from 
performance of the 1H variable temperature NMR experiments could not be made for differing 
conformers as we had previously anticipated. 
While the variable temperature experimental data could not be used to afford experimental 
values for the calculation of Gibbs free energy, it did offer some explanation as to why both the 
isolated compound 1 product and the mixture of various constituents both provided nearly 
quantitative yields of the subsequent product during the multistep synthesis of the final DiPODS 
product when utilized. As shown by the trends of Tables 4.2 and 4.3, the integration values of 
peaks associated with the compound 1 product (set A) increased with increasing temperature over 
time while the peaks associated with both the imidic acid tautomers of the compound 1 product 
and the doubly Boc-protected variant decrease. While small amounts of the minor mixture 
constituents likely contribute to the increasing amounts of degraded material that were also 
observed within the 1H NMR spectra, they also contribute to the increasing proportions of anti-1 
observed in the spectra over time through either tautomerizing from imidic acid to the amide or by 




Table 4.2. Percentages (%) and differences in percentages (%) between compound 1 isomeric mixture components at the initial 






























24.3 36.7 39.0 0.0 0.0 
0.04 0.54 -0.58 0.00 0.00 
50 24.3 37.3 38.4 0.0 0.0 
0 
75 
25.8 36.3 34.9 1.2 1.7 
4.14 -0.41 -9.15 1.92 3.50 
50 29.9 35.9 25.8 3.1 5.2 
0 
80 
31.7 35.7 22.6 3.5 6.5 
5.23 -0.68 -9.78 1.94 3.28 
50 36.9 35.1 12.8 5.4 9.8 
0 
85 
38.6 34.7 9.9 5.9 11.0 
5.17 -2.33 -6.43 1.50 2.09 
50 43.7 32.3 3.4 7.4 13.1 
0 
90 
44.9 31.7 2.1 7.7 13.6 
7.88 -7.25 -2.06 0.53 0.90 






Table 4.3. Percentages (%) and differences in percentages (%) between compound 1 isomeric mixture components at the initial 

























24.2 35.3 40.3 0.16 
-0.50 0.41 0.07 0.02 
50 23.7 35.7 40.4 0.18 
0 
75 
26.4 35.1 37.9 0.6 
0.67 -0.28 -1.3 0.93 
40 27.0 34.8 36.6 1.6 
0 
80 
28.5 34.7 34.7 2.1 
3.79 -0.63 -5.3 2.1 
50 32.3 34.1 29.4 4.2 
0 
85 
33.5 34.3 27.1 5.1 
4.76 -0.55 -6.9 2.7 
50 38.3 33.7 20.2 7.8 
0 
95 
40.2 33.6 17.3 8.9 
7.80 -1.57 -10.7 4.4 
90 48.0 32.0 6.61 13.3 
0 
-40 
45.7 32.4 8.19 13.7 
0.38 -0.69 0.01 0.29 







4.4. Conclusions & Future Directions. 
In summary, this chapter reports the synthesis of compounds 1-4 and 7 which were 
ultimately applied towards production of the novel disulfide-rebridging DiPODS bioconjugation 
reagent. 1H variable temperature NMR experimentation did not afford data from which Gibbs free 
energy values could be calculated for the hypothesized rotameric species of the compound 1 crude 
product mixture. However, these experiments, in combination with FTIR spectroscopic analysis, 
enabled structural identification of the mixture constituents. The effects of increased temperature, 
such as that applied during the subsequent reaction of the multistep synthetic procedure, were 
observed to afford increasing amounts of the major compound 1 anti-rotameric constituents and 
thermal deprotection products; isobutylene and dimethyl 5-aminoisophthalate. Increasing the 
temperature of the dissolved compound 1 crude product mixture also resulted in the reduced 
concentration of doubly Boc-protected and imidic acid tautomer product variants [(Boc)2-1 and 
tautomer-1]. Finally, a fourth set of peaks was observed upon heating the product mixture sample. 
Based on the computational models performed by Dr. Khozeimeh Sarbisheh, we believe this fourth 
set of peaks is attributed to the formation of syn-rotamers of compound 1. The efforts outlined 
within this chapter, in combination with those of Dr. Khozeimeh Sarbisheh and our collaborators 
in Dr. Zeglis’s lab, are summarized in a recently published manuscript.  
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General Discussion & Conclusion 
As a whole, the primary objective of this thesis was to explore and improve the application 
and methodologies associated with radiochemistry. The research discussed in this dissertation 
mirror the multifaceted nature of this field. What started out as a simple application of pre-existing 
methodologies in Chapter 2 with the attempted 19F/18F-transfluorination of the CDy11 BODIPY 
dye developed into a new research objective that sought to address the complications experienced 
with CDy11 and improve the existing labeling strategies. While this project requires further 
investigative efforts to flesh out its bones, the work presented in Chapter 3 is a step forward 
towards reliable and reproducible synthesis of BODIPY-based radiotracers. To our knowledge, 
this project afforded the first application of air stable Mg(NO3)2·6H2O solutions towards the 
synthesis of a 18F-labeled BODIPY fluorophore. Future research endeavors should investigate the 
efficacy of a wide range of stable Lewis acids towards facilitating 19F/18F-isotopic exchange at the 
BF2-moiety. In doing such, GMP certification could be achieved for BODIPY-based imaging 
agents; opening the door to a greater number of potential PET diagnostic agents.  
The research outlined in Chapter 3 pertained to the performance of 19F/18F-fluoride 
exchange on a BODIPY core hosting relatively inert functional groups which contributed 
negligible electron donating or withdrawing effects to the quasi-aromatic framework. Future 
initiatives should focus on surveying the effects of various functional groups and their position on 
the planar ring system on the radiochemical yields obtained from the 19F/18F-transfluorination 
process. A library of this nature would provide further insight into optimal design characteristics 
for synthesis of novel BODIPY precursors and the radiolabeling conditions best suited to transform 
them into bimodal imaging agents. 
 The research focus shifted in Chapter 4 from the application and investigation of improved 
radiolabeling methodologies previously discussed in Chapters 2 and 3 to improving the stability 
and subsequently the delivery of radioimmunoconjugate. By taking note of the observations made 
between the multistep reactions 1 and 2 and the 1H NMR compound 1 crude mixture spectra it was 
discerned that further purification processes were not required before progressing to the next stage 
of the synthesis. Spectroscopic analysis of the isomers and crude mixture constituents of 
compound 1 from the multistep DiPODS synthesis provides further insight towards the synthetic 
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process as a whole. This effectively increased the amount of available reagent material for the 
subsequent reaction from 66% to nearly quantitative values as those used during the first reaction 
as the reaction of all the compound 1 crude mixture components were able to form the subsequent 
compound 2 product under the applied reaction conditions. What’s more, performing these 
spectroscopic analyses and reporting the observations and lessons learned from our findings proves 
beneficial for future synthetic strategy development and the investigation of means by which to 
optimize the overall reaction yields of multistage processes. These efforts were incorporated into 
a manuscript accompanying the contributions made by Dr. Khozeimeh Sarbisheh and our 
collaborators in Dr.  eglis’s lab outlining the successful synthesis and ex vivo disulfide rebridging 
assessment of the DiPODS linker molecule.. Future research efforts may aim to modify the 
DiPODS structure to optimize the linker structure further as well as in vivo experimentation. 
In summary, the various approaches and research interests outlined in this dissertation 
provide further insight towards improving future radiotherapeutics and PET diagnostics. In doing 
such, these efforts serve towards the future expansion of the toolbox of applicable radiochemical 







Figure A.1. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 50 eq SnCl4, 37C, TBAB fixing agent at 





Figure A2. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 50 eq SnCl4, 37C, TBAB fixing agent. 
Chromatogram obtained using Thermo Fisher Vanquish UHPLC system equipped with 
radioactivity detector set at 2000K sensitivity. Peak associated with the radiolabeled commercial 





Figure A3. Representative HPLC chromatogram of commercial BODIPY standard. 
Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system equipped with a 





Figure A4. Representative TLC chromatogram of [19F/18F]-isotopic exchange reaction 
mixture for commercial BODIPY standard when subjected to 10 eq SnCl4, 37 °C, TBAB fixing 
agent. Experimental conditions applied are outlined in entry 1 of Table 3.2. Chromatogram 
obtained using Bioscan AR-2000 radio-TLC plate reader. The radioactivity peak associated with 
free [18F]F- is labeled as such.  
  







Figure A5. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 10 eq Mg(NO3)2, 55.8 eq TEAB fixing agent at 37 
C for 5 minutes. Experimental conditions applied are outlined in entry 1 of Table 3.2. 
Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system equipped with a 





Figure A6. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 10 eq Mg(NO3)2, 55.8 eq TEAB fixing agent at 37 
C for 5 minutes. Experimental conditions applied are outlined in entry 1 of Table 3.2. 
Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system equipped with a 
radioactivity detector set to 2000K sensitivity. Peak associated with the radiolabeled commercial 



































Figure A7. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 25 eq Mg(NO3)2, 37 C, 55.8 eq TEAB fixing 
agent for 5 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. This 
data is associated with entry 2 of Table 3.2. The radioactivity peak associated with free [18F]F- is 




































Figure A8. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture 
for commercial BODIPY standard when subject to 25 eq Mg(NO3)2, 37 C, 55.8 eq 
TEAB fixing agent for 15 minutes. Chromatogram obtained using Bioscan AR-2000 
radio-TLC plate reader. This data is associated with entry 2 of Table 3.2. The 
radioactivity peak associated with free [18F]F- is labeled as such while the product peak 






























Figure A9. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 25 eq Mg(NO3)2, 37 C, 55.8 eq TEAB fixing 
agent for 30 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. 
This data is associated with entry 2 of Table 3.2. The radioactivity peak associated with free [18F]F- 







































Figure A10. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 25 eq Mg(NO3)2, 37 C, 55.8 eq TEAB 
fixing agent for 45 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC 
plate reader. This data is associated with entry 2 of Table 3.2. The radioactivity peak 





Figure A11. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 25 eq Mg(NO3)2, 55.8 eq TEAB fixing agent at 37 
C for 5 minutes. Experimental conditions applied are outlined in entry 2 of Table 3.2. 
Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system equipped with a 
UV-Vis detector set to measure at 505 nm. Peak 2 (7.108 min) is associated with the commercial 




Figure A12. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 25 eq Mg(NO3)2, 55.8 eq TEAB fixing agent at 37 
C for 5 minutes. Experimental conditions applied are outlined in entry 2 of Table 3.2. 
Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system equipped with a 
radioactivity detector set to 2000K sensitivity. Peak associated with the radiolabeled commercial 


































Figure A13. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 50 eq Mg(NO3)2, 37 C, 55.8 eq TEAB fixing 
agent for 5 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. This 
data is associated with entry 3 of Table 3.2. The radioactivity peak associated with free [18F]F- is 
































Figure A14. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 50 eq Mg(NO3)2, 37 C, 55.8 eq TEAB fixing 
agent for 15 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. 
This data is associated with entry 3 of Table 3.2. The radioactivity peak associated with free 


































Figure A15. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 50 eq Mg(NO3)2, 37 C, 55.8 eq TEAB fixing 
agent for 30 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. 
This data is associated with entry 3 of Table 3.2. The radioactivity peak associated with free 



































Figure A16. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 50 eq Mg(NO3)2, 37 C, 55.8 eq TEAB fixing 
agent for 45 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. 
This data is associated with entry 3 of Table 3.2. The radioactivity peak associated with free 




Figure A17. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 50 eq Mg(NO3)2, 55.8 eq TEAB fixing agent at 37 
C for 30 minutes. Experimental conditions applied are outlined in entry 3 of Table 3.2. 
Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system equipped with a 
UV-Vis detector set to measure at 505 nm. Peak 1 (7.125 min) is associated with the commercial 




Figure A18. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 50 eq Mg(NO3)2, 55.8 eq TEAB fixing agent at 37 
C for 30 minutes. Experimental conditions applied are outlined in entry 3 of Table 3.2. 
Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system equipped with a 
radioactivity detector set to 2000K sensitivity. Peak associated with the radiolabeled commercial 







































Figure A19. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 37 C, 55.8 eq TEAB fixing 
agent for 5 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. This 
data is associated with entry 4 of Table 3.2. The radioactivity peak associated with free [18F]F- is 















































Figure A20. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for commercial 
BODIPY standard when subject to 100 eq Mg(NO3)2, 37 C, 55.8 eq TEAB fixing agent for 15 minutes. 
Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. This data is associated with 
entry 4 of Table 3.2. The radioactivity peak associated with free [18F]F- is labeled as such while the 




Figure A21. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 37 C, 55.8 eq TEAB fixing 
agent for 30 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. 
This data is associated with entry 4 of Table 3.2. The radioactivity peak associated with free [18F]F- 



























































Figure A22. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for commercial 
BODIPY standard when subject to 100 eq Mg(NO3)2, 37 C, 55.8 eq TEAB fixing agent for 45 minutes. 
Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. This data is associated with 
entry 4 of Table 3.2. The radioactivity peak associated with free [18F]F- is labeled as such while the 




Figure A23. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 55.8 eq TEAB fixing agent at 
37 C for 5 minutes. Experimental conditions applied are outlined in entry 4 of Table 3.2. 
Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system equipped with a 
UV-Vis detector set to measure at 505 nm. Peak 2 (8.258 min) is associated with the commercial 




Figure A24. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 55.8 eq TEAB fixing agent at 
37 C for 5 minutes. Experimental conditions applied are outlined in entry 4 of Table 3.2. 
Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system equipped with a 
radioactivity detector set to 2000K sensitivity. Peak associated with the radiolabeled commercial 
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Figure A25. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 150 eq Mg(NO3)2, 37 C, 55.8 eq TEAB fixing 
agent for 5 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. This 
data is associated with entry 5 of Table 3.2. The radioactivity peak associated with free [18F]F- is 
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Figure A26. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 150 eq Mg(NO3)2, 37 C, 55.8 eq TEAB fixing 
agent for15 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. 
This data is associated with entry 5 of Table 3.2. The radioactivity peak associated with free 
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Figure A27. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 150 eq Mg(NO3)2, 37 C, 55.8 eq TEAB fixing 
agent for 30 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. 
This data is associated with entry 5 of Table 3.2. The radioactivity peak associated with free 
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Figure A28. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 150 eq Mg(NO3)2, 37 C, 55.8 eq TEAB fixing 
agent for 45 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. 
This data is associated with entry 5 of Table 3.2. The radioactivity peak associated with free 





Figure A29. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 150 eq Mg(NO3)2, 55.8 eq TEAB fixing agent at 
37 C for 5 minutes. Experimental conditions applied are outlined in entry 5 of Table 3.2. 
Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system equipped with a 
UV-Vis detector set to measure at 505 nm. Peak 1 (7.142 min) is associated with the commercial 




Figure A30. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 150 eq Mg(NO3)2, 55.8 eq TEAB fixing agent at 
37 C for 5 minutes. Experimental conditions applied are outlined in entry 5 of Table 3.2. 
Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system equipped with a 
radioactivity detector set to 2000K sensitivity. Peak associated with the radiolabeled commercial 
































Figure A31. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 37 C, 27.9 eq TEAB fixing 
agent for 5 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. This 
data is associated with entry 6 of Table 3.2. The radioactivity peak associated with free [18F]F- is 





Figure A32. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 37 C, 27.9 eq TEAB fixing 
agent for 15 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. 
This data is associated with entry 6 of Table 3.2. The radioactivity peak associated with free [18F]F- 










Figure A33. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 37 C, 27.9 eq TEAB fixing 
agent for 30 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. 
This data is associated with entry 6 of Table 3.2. The radioactivity peak associated with free [18F]F- 









Figure A34. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 37 C, 27.9 eq TEAB fixing 
agent for 45 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. 
This data is associated with entry 6 of Table 3.2. The radioactivity peak associated with free [18F]F- 









Figure A35. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 27.8 eq TEAB fixing agent at 
37 C for 5 minutes. Experimental conditions applied are outlined in entry 6 of Table 3.2. 
Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system equipped with a 
UV-Vis detector set to measure at 505 nm. Peak 1 (7.108 min) is associated with the commercial 




Figure A36. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 27.8 eq TEAB fixing agent at 
37 C for 5 minutes. Experimental conditions applied are outlined in entry 6 of Table 3.2. 
Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system equipped with a 
radioactivity detector set to 2000K sensitivity. Peak associated with the radiolabeled commercial 











* . 2  
Figure A37. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 75.0 eq TEAB fixing agent for 
5 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. This data is 
associated with entry 7 of Table 3.2. The radioactivity peak associated with free [18F]F- is labeled 
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Figure A38. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 75.0 eq TEAB fixing agent for 
15 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. This data is 
associated with entry 7 of Table 3.2. The radioactivity peak associated with free [18F]F- is labeled 
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Figure A39. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 75.0 eq TEAB fixing agent for 
30 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. This data is 
associated with entry 7 of Table 3.2. The radioactivity peak associated with free [18F]F- is labeled 
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Figure A40. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 75.0 eq TEAB fixing agent for 
45 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC plate reader. This data is 
associated with entry 7 of Table 3.2. The radioactivity peak associated with free [18F]F- is labeled 




Figure A41. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 75.0 eq TEAB fixing agent at 
37 C for 5 minutes. Experimental conditions applied are outlined in entry 7 of Table 3.2. 
Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system equipped with a 
UV-Vis detector set to measure at 505 nm. Peak 3 (7.158 min) is associated with the commercial 




Figure A42. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2, 75.0 eq TEAB fixing agent at 
37 C for 5 minutes. Experimental conditions applied are outlined in entry 7 of Table 3.2. 
Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system equipped with a 
radioactivity detector set to 2000K sensitivity. Peak associated with the radiolabeled commercial 








































Figure A43. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2 prepared in DMSO, 37 
C, 55.8 eq TEAB fixing agent for 5 minutes. Chromatogram obtained using Bioscan AR-
2000 radio-TLC plate reader. This data is associated with entry 8 of Table 3.2. The 
radioactivity peak associated with free [18F]F- is labeled as such while the product peak is 





Figure A44. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2 prepared in DMSO, 37 C, 55.8 
eq TEAB fixing agent for 15 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC 
plate reader. This data is associated with entry 8 of Table 3.2. The radioactivity peak associated 






































Figure A45. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2 prepared in DMSO, 37 C, 55.8 
eq TEAB fixing agent for 30 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC 
plate reader. This data is associated with entry 8 of Table 3.2. The radioactivity peak associated 





Figure A46. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2 prepared in DMSO, 37 C, 55.8 
eq TEAB fixing agent for 45 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC 
plate reader. This data is associated with entry 8 of Table 3.2. The radioactivity peak associated 












Figure A47. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2 (DMSO solution), 55.8 eq TEAB 
fixing agent at 37 C for 5 minutes. Experimental conditions applied are outlined in entry 8 of 
Table 3.2. Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system 
equipped with a UV-Vis detector set to measure at 505 nm. Peak 1 (7.108 min) is associated with 




Figure A48. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 100 eq Mg(NO3)2 (DMSO solution), 55.8 eq TEAB 
fixing agent at 37 C for 5 minutes. Experimental conditions applied are outlined in entry 8 of 
Table 3.2. Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system 
equipped with a radioactivity detector set to 2000K sensitivity. Peak associated with the 







































Figure A49. TLC chromatogram of [19F/18F]-isotopic exchange reaction 
mixture for commercial BODIPY standard when subject to 10 eq Mg(NO3)2 with 
excess H2O, 37 C, 55.8 eq TEAB fixing agent for 5 minutes. Chromatogram 
obtained using Bioscan AR-2000 radio-TLC plate reader. This data is associated with 
entry 9 of Table 3.2. The radioactivity peak associated with free [18F]F- is labeled as 
































Figure A50. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 10 eq Mg(NO3)2 with excess H2O, 37 C, 55.8 eq 
TEAB fixing agent for 15 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC 
plate reader. This data is associated with entry 9 of Table 3.2. The radioactivity peak associated 







































Figure A51. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture 
for commercial BODIPY standard when subject to 10 eq Mg(NO3)2 with excess H2O, 
37 C, 55.8 eq TEAB fixing agent for 30 minutes. Chromatogram obtained using 
Bioscan AR-2000 radio-TLC plate reader. This data is associated with entry 9 of Table 
3.2. The radioactivity peak associated with free [18F]F- is labeled as such while the 

































Figure A52. TLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 10 eq Mg(NO3)2 with excess H2O, 37 C, 55.8 eq 
TEAB fixing agent for 45 minutes. Chromatogram obtained using Bioscan AR-2000 radio-TLC 
plate reader. This data is associated with entry 9 of Table 3.2. The radioactivity peak associated 




Figure A53. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 10 eq Mg(NO3)2 (excess H2O present), 55.8 eq 
TEAB fixing agent at 37 C for 5 minutes. Experimental conditions applied are outlined in entry 
9 of Table 3.2. Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system 
equipped with a UV-Vis detector set to measure at 505 nm. Peak 1 (7.108 min) is associated with 




Figure A54. HPLC chromatogram of [19F/18F]-isotopic exchange reaction mixture for 
commercial BODIPY standard when subject to 10 eq Mg(NO3)2 ((excess H2O present),), 55.8 eq 
TEAB fixing agent at 37 C for 5 minutes. Experimental conditions applied are outlined in entry 
9 of Table 3.2. Chromatogram was obtained using a Thermo Fisher Vanquish UHPLC system 
equipped with a radioactivity detector set to 2000K sensitivity. Peak associated with the 




Table A1. Line commands for Trasis miniAIO 18F-solution preparation.  Line advance comments correspond to setting 
commands on the Trasis mini AIO software such as command duration (measured in seconds (s) and minutes (m), heater (H1), vacuum 
(V), activity pump (P), and syringe actuators (where either SA1 and SA2 were used as the activity pump inlet and solution draw up/elute 
systems respectively). Pressure and vacuum are reported in pound per square inch (psi). Pressure flow setting is reported upon use of 
pressurized nitrogen gas within the Trasis mini AIO radiosynthesis module as either being high flow (HF) or low flow (LF). Cassette 
rotory positioning is reported as the visual flow path through the cassette during the associated line command. SA1 and SA2 volumes 
are reported in mililitre (mL) values for each line number along with the rates at which these syringe positions were set to draw up or 
elute their set contents (mL/min). Finally, reactor heat is presented in degrees Celsius (°C). Vacuum activation at the bottom left of the 

















0 Zeroing the Activity Sensors Starting SA1       - - - - - - 0 
2 Ready to receive activity  Ready to Receive 500  -100 - - - - - - 0 
3 Activity Received 
Activity 
Received 
  500   -100 - - - - - - 0 
4 Start Synthesis  Start Synthesis 500  -100 - - - - - - 0 
5 Activity In Position   
Insert Activity into 
Syringe 
500 HF -800 ⌟ ⌞ ⌟ - - - 0 
6 Recovering [18O]-H2O  SA1 500 HF -800 ⌟ ⌞ ⌟ - - - 0 
7 Recovering [18O]-H2O   20 s 500 HF -800 ⌟ ⌞ ⌟ - - - 0 























9 Recovering [18O]-H2O   60 s 500 HF -800 ⌟ ⌞ ⌟ - - - 0 
10 Pressure to Fixing Agent Vial  4 s 500 LF 0 - - - ⌟ - - 0 
11 Fixing Agent Elute   12s 0   0 - - - ⌞ - - 1 
12 Fixing Agent Elute  H1, P, SA1, SA2, V 500 HF 0 - - - - - - 1 
13 Fixing Agent Elute   H1, P, SA2, V 0   0 ⌞ - - - - - 1 
14 Fixing Agent Elute  H1, P, SA1, V 500 LF -300 ⌟ ⌞ ⌟ - - - 1 
15 Fixing Agent Elute   2 m 500 LF -300 ⌟ ⌞ ⌟ - - - 1 
16 Heat With Vacuum  4 m 100 LF -40 - - ⌟ - - - 1 
17 Heat With Vacuum   4 m 200 LF -200 - - ⌟ - - - 1 
18 Heat With Vacuum  2 m 400 LF -500 - - ⌟ - - - 1 
19 Heat With Vacuum   20 s 500 HF -1000 - - ⌟ - - - 1 
20 Pressurize Acetonitrile Vial  5 s 500 LF 0 - - - - - ⌟ 0 
21 Draw up 1 mL Acetonitrile   3 s 500   -300 - - - - - ⌞ 0 
22 Extra Air   H1, P, SA2, V 500 LF 0 - - - - - - 0 
23 Add Acetonitrile   H1, P, SA2, V 0   0 ⌞ - - - - - 0 
24 Add Acetonitrile  45 s 500 LF -300 ⌟ ⌞ ⌟ - - - 1 
25 Extra Air Flush   5 s 500 LF -300 ⌟ ⌞ ⌟ - - - 1 
26 Heat With Vacuum  2 m 100 LF -40 - - ⌟ - - - 1 























28 Heat With Vacuum  2 m 500 LF -500 - - ⌟ - - - 1 
29 Heat With Vacuum   20 s 500   -1000 - - ⌟ - - - 1 
30 Pressurize Acetonitrile Vial  5 s 500 LF 0 - - - - - ⌟ 0 
31 Draw up 1 mL Acetonitrile   H1, P, SA2, V 0   0 - - - - - ⌞ 0 
32 Draw up 1 mL Acetonitrile  3 s 0  0 - - - - - ⌞ 0 
33 Extra Air    H1, P, SA2, V 500 LF 0 - - - - - - 0 
34 Add Acetonitrile  H1, P, SA2, V 0  -300 - - ⌞ - - - 1 
35 Extra Air Flush   5 s 500 LF -300 - - - - - - 1 
36 Heat With Vacuum  60 s 100 LF -40 - - ⌟ - - - 1 
37 Heat With Vacuum   60 s 300 LF -200 - - ⌟ - - - 1 
38 Heat With Vacuum  2 m 500 LF -500 - - ⌟ - - - 1 
39 Heat With Vacuum   20 s 500 HF -1000 - - ⌟ - - - 1 
40 Pressurize Acetonitrile Vial  5 s 500 LF 0 - - - - - ⌟ 0 
41 Draw up 1 mL Acetonitrile   H1, P, SA2, V 0   0 - - - - - ⌞ 0 
42 Draw up 1 mL Acetonitrile  3 s 0  0 - - - - - ⌞ 0 
43 Extra Air    H1, P, SA2, V 500 LF 0 - - - - - - 0 
44 Add Acetonitrile  H1, P, SA2, V 0  -300 - - ⌞ - - - 1 
45 Extra Air Flush   5 s 300 LF -300 - - ⌟ - - - 1 























47 Heat With Vacuum   60 s 300 LF -200 - - ⌟ - - - 1 
48 Heat With Vacuum  2 m 500 LF -500 - - ⌟ - - - 1 
49 Heat With Vacuum   20 s 500 HF -1000 - - ⌟ - - - 1 
50 Cool Down  12 m 500 HF -1000 - - ⌟ - - - 1 
51 
Pressurize Reconstitution 
Acetonitrile Vial   
  10 s 500 LF 0 - - - - ⌟ - 0 
52 
Rinse line with Acetonitrile to 
Clean 
 3 s 0  0 - - - - ⌞ - 1 
53 
Rinse line with Acetonitrile to 
Clean 
  H1, P, SA2, V 300 LF 0 - - - - - - 1 
54 
Rinse line with Acetonitrile to 
Clean 
 H1, P, SA2, V 0  -300 - - ⌞ - - - 1 
55 
Pressurize Reconstitution 
Acetonitrile Vial  
  5 s 500 LF 0 - - ⌟ - - - 0 
56 
Draw up 3 mL Reconstitution 
Acetonitrile 
 10 s 0  0 - - ⌞ - - - 0 




 H1, P, SA2, V 0  -300 - - ⌞ - - - 1 
59 
Pressurize Reactor Vessel to 
Move Contents 
  5 s 500 LF 0 - - ⌟ - - - 0 























61 Draw Up Extra Air   H1, P, SA2, V 0 LF 0 - - - - - - 0 
62 
Deliver Product to Product 
Vial 
 H1, P, SA2, V 0  0 - - ⌞ - - - 1 









Cassette Rotory Positioning 
(Positions 7-12) 
SA1 SA2 Reactor Heat (ºC)  
0 - - - - - / 6 mL     
2 - - - - - /    
3 - - - - - /       
4 - - - - - /    
5 ⌞ ⌟ - - - / 6 mL 0 mL   




7 ⌞ ⌟ - - - /     95 
8 ⌞ ⌟ - - - /   95 
9 ⌞ ⌟ - - - /     95 
10 - - - - - / 6 mL  95 












14 - ⌞ ⌟ - - / 6 mL  95 








Cassette Rotory Positioning 
(Positions 7-12) 
SA1 SA2 Reactor Heat (ºC)  
16 - ⌞ ⌟ - - /   95 
17 - ⌞ ⌟ - - /     95 
18 - ⌞ ⌟ - - /   95 
19 - ⌞ ⌟ - - /     95 
20 - - - - - / 6 mL  95 












24 - ⌞ ⌟ - - /   95 
25 - ⌞ ⌟ - - /     95 
26 - ⌞ ⌟ - - /   95 
27 - ⌞ ⌟ - - /     95 
28 - ⌞ ⌟ - - /   95 
29 - ⌞ ⌟ - - /     95 
30 - - - - - / 6 mL  95 











Cassette Rotory Positioning 
(Positions 7-12) 
SA1 SA2 Reactor Heat (ºC)  












35 - ⌞ ⌟ - - /     95 
36 - ⌞ ⌟ - - /   95 
37 - ⌞ ⌟ - - /     95 
38 - ⌞ ⌟ - - /   95 
39 - ⌞ ⌟ - - /     95 
40 - - - - - / 6 mL  95 


















Line Number  
Cassette Rotory Positioning 
(Positions 7-12) 
SA1 SA2 Reactor Heat (ºC)  




45 - ⌞ ⌟ - - /     110 
46 - ⌞ ⌟ - - /   110 
47 - ⌞ ⌟ - - /     110 
48 - ⌞ ⌟ - - /   110 
49 - ⌞ ⌟ - - /     110 
50 - ⌞ ⌟ - - /   50 
51 - - - - - /     50 












55 - - - - - / 6 mL   50 














Line Number  
Cassette Rotory Positioning 
(Positions 7-12) 
SA1 SA2 Reactor Heat (ºC)  




59 - ⌞ ⌟ - - / 6 mL   50 






















Figure A55. 1H NMR spectrum of compound 1 crude mixture before precipitation in DMSO-d6. Peaks associated with the anti-
rotamers of compound 1 (anti-1, set A, ), a doubly Boc-protected derivative of compound 1 [(Boc)2-1, set B, §), and an imidic acid 
tautomers of compound 1 (tautomer-1, set C, ■) are designated by the symbols , § and ■ respectively. Peaks associated with water are 
labeled with the symbol *. Peaks associated with residual EtOAc are denoted by the symbol ◊. (For simplicity, only one stereoisomer 








Figure A56. 13C{1H}-UDEFT NMR spectrum of compound 1 crude mixture before precipitation or column chromatography in 
DMSO-d6. The crude mixture containes compound 1’s anti-rotamers (anti-1, set A), a doubly Boc-protected derivative of compound 1 










Figure A57. 1H NMR spectrum of the anti-rotamers of compound 1 (anti-1, set A, ) in DMSO-d6. For simplicity, only one 









Figure A58. 13C{1H}-UDEFT NMR spectrum of anti-rotamers (set A) of compound 1 in DMSO-d6. Peak associated with DCM 








Figure A59. 1H NMR spectrum of compound 2 in DMSO-d6. Peak associated with water residue is denoted with the symbol 









Figure A60. 13C{1H}-UDEFT NMR spectrum of compound 2 in DMSO-d6. Peaks associated with EtOH residues are denoted 








Figure A61. 1H NMR spectrum of compound 3 in DMSO-d6. Peak associated with water residue is denoted with the symbol (*). 
Peaks associated with EtOAc residues are denoted with the symbol (). The presence of residual Di-tert-butyl decarbonate impurity 








Figure A62. 13C{1H}-UDEFT NMR spectrum of compound 3 in DMSO-d6. Peaks associated with EtOAc residues are denoted 








Figure A63. 1H NMR spectrum of compound 4 in DMSO-d6. Peak associated with water residue is denoted with the symbol (*). 








Figure A64. 13C{1H}-UDEFT NMR spectrum of compound 4 in DMSO-d6. Peaks associated with EtOAc residues are denoted 








Figure A65. 1H NMR spectrum of compound 7 in DMSO-d6. Peak associated with water residue is denoted with the symbol (*). 

















Figure A67. 1H NMR spectrum of the anti-rotamers of compound 1 in DMSO-d6 solvent at 25 °C. Peaks associated with set A 






















Figure A68. 1H NMR spectrum of the anti-rotamers of compound 1 in DMSO-d6 solvent at 75 °C. Peaks associated with set A 























Figure A69. 1H NMR spectrum of the anti-rotamers of compound 1 in DMSO-d6 solvent at 80 °C. Peaks associated with set A 
(anti-1) and the deprotected derivative of compound 1 are designated by the symbols  and ӿ respectively. Figure reported in 


































Figure A70. 1H NMR spectrum of the anti-rotamers of compound 1 in DMSO-d6 solvent at 85 °C. Peaks associated with set A 
(anti- 1) and the deprotected derivative of compound 1 are designated by the symbols  and ӿ respectively. Figure reported in 





























Figure A71. 1H NMR spectrum of the anti-rotamers of compound 1 in DMSO-d6 solvent at 90 °C. Peaks associated with set A 
(anti-1) and the deprotected derivative of compound 1 are designated by the symbols  and ӿ respectively. Figure reported in 






























Figure A72. 1H NMR spectrum of compound 1 product mixture in DMSO-d6 solvent at 25 °C. Peaks associated with set A (anti-
rotamers of compound 1, anti-1), set B [doubly Boc-protected derivative of compound 1, (Boc)2-1], and set C (imidic acid tautomers of 
compound 1, tautomer-1) are designated by the symbols , § and ■ respectively. Peak associated with water residue is labeled with the 





























Figure A73. 1H NMR spectrum of compound 1 product mixture in DMSO-d6 solvent at 75 °C. Peaks associated with set A (anti-
rotamers of compound 1, anti-1), set B [doubly Boc-protected derivative of compound 1, (Boc)2-1], set C (imidic acid tautomers of 
compound 1, tautomer-1), set D (syn-rotamers of compound 1, syn-1), and the deprotected derivative of compound 1 are designated by 
the symbols , §, ■, ▲, and ӿ respectively. Peak associated with water residue is labeled with the symbol *. Peak associated with 
residual DCM solvent is denoted by the symbol +. Peaks associated with isobutylene are denoted by the symbol †. Figure reported in 








Figure A74. 1H NMR spectrum of compound 1 product mixture in DMSO-d6 solvent at 80 °C. Peaks associated with set A (anti-
rotamers of compound 1, anti-1), set B [doubly Boc-protected derivative of compound 1, (Boc)2-1], set C (imidic acid tautomers of 
compound 1, tautomer-1), set D (syn-rotamers of compound 1, syn-1), and the deprotected derivative of compound 1 are designated by 
the symbols , §, ■, ▲, and ӿ respectively. Peak associated with water residue is labeled with the symbol *. Peak associated with 
residual DCM solvent is denoted by the symbol +. Peaks associated with isobutylene are denoted by the symbol †. Figure reported in 








Figure A75. 1H NMR spectrum of compound 1 product mixture in DMSO-d6 solvent at 85 °C. Peaks associated with set A (anti-
rotamers of compound 1, anti-1), set B [doubly Boc-protected derivative of compound 1, (Boc)2-1], set C (imidic acid tautomers of 
compound 1, tautomer-1), set D (syn-rotamers of compound 1, syn-1), and the deprotected derivative of compound 1 are designated by 
the symbols , §, ■, ▲, and ӿ respectively. Peak associated with water residue is labeled with the symbol *. Peak associated with 
residual DCM solvent is denoted by the symbol +. Peaks associated with isobutylene are denoted by the symbol †. Figure reported in 








Figure A76. 1H NMR spectrum of compound 1 product mixture in DMSO-d6 solvent at 90 °C. Peaks associated with set A (anti-
rotamers of compound 1, anti-1), set B [doubly Boc-protected derivative of compound 1, (Boc)2-1], set C (imidic acid tautomers of 
compound 1, tautomer-1), set D (syn-rotamers of compound 1, syn-1), and the deprotected derivative of compound 1 are designated by 
the symbols , §, ■, ▲, and ӿ respectively. Peak associated with water residue is labeled with the symbol *. Peak associated with 
residual DCM solvent is denoted by the symbol +. Peaks associated with isobutylene are denoted by the symbol †. Figure reported in 








Figure A77. 1H NMR spectrum of the anti-rotamers of compound 1 in DMSO-d6 solvent at 25 °C to 90 °C. Peaks associated 








Figure A78. 1H NMR spectrum of the anti-rotamers of compound 1 in DMF-d7 solvent at 25 °C. Peaks associated with set A 






















Figure A79. 1H NMR spectrum of the anti-rotamers of compound 1 in DMF-d7 solvent at 75 °C. Peaks associated with set A 























Figure A80. 1H NMR spectrum of the anti-rotamers of compound 1 in DMF-d7 solvent at 80 °C. Peaks associated with set A 






















Figure A81. 1H NMR spectrum of the anti-rotamers of compound 1 in DMF-d7 solvent at 85 °C. Peaks associated with set A 






















Figure A82. 1H NMR spectrum of the anti-rotamers of compound 1 in DMF-d7 solvent at 90 °C. Peaks associated with set A 






















Figure A83. 1H NMR spectrum of the anti-rotamers of compound 1 in DMF-d7 solvent at -40 °C. Peaks associated with set A 






















Figure A84. 1H NMR spectrum of compound 1 product mixture in DMF-d7 solvent at 25 °C. Peaks associated with set A (anti-
rotamers of compound 1, anti-1), set B [doubly Boc-protected derivative of compound 1, (Boc)2-1], and set C (imidic acid tautomers of 





























Figure A85. 1H NMR spectrum of compound 1 product mixture in DMF-d7 solvent at 75 °C. Peaks associated set A (anti-
rotamers of compound 1, anti-1), set B [doubly Boc-protected derivative of compound 1, (Boc)2-1], and set C (imidic acid tautomers of 
compound 1, tautomer-1), and the deprotected derivative of compound 1 are designated by the symbols , §, ■, and ӿ respectively. Peak 

































Figure A86. 1H NMR spectrum of compound 1 product mixture in DMF-d7 solvent at 80 °C. Peaks associated with set A (anti-
rotamers of compound 1, anti-1), set B [doubly Boc-protected derivative of compound 1, (Boc)2-1], and set C (imidic acid tautomers of 
compound 1, tautomer-1), and the deprotected derivative of compound 1 are designated by the symbols , §, ■, and ӿ respectively. Peak 


































Figure A87. 1H NMR spectrum of compound 1 product mixture in DMF-d7 solvent at 85 °C. Peaks associated with set A (anti-
rotamers of compound 1, anti-1), set B [doubly Boc-protected derivative of compound 1, (Boc)2-1], and set C (imidic acid tautomers of 
compound 1, tautomer-1), and the deprotected derivative of compound 1 are designated by the symbols , §, ■, and ӿ respectively. Peak 




































Figure A88. 1H NMR spectrum of compound 1 product mixture in DMF-d7 solvent at 90 °C. Peaks associated with set A (anti-
rotamers of compound 1, anti-1), set B [doubly Boc-protected derivative of compound 1, (Boc)2-1], and set C (imidic acid tautomers of 
compound 1, tautomer-1), and the deprotected derivative of compound 1 are designated by the symbols , §, ■, and ӿ respectively. Peak 




































Figure A89. 1H NMR spectrum of compound 1 product mixture in DMF-d7 solvent at -40 °C. Peaks associated set A (anti-
rotamers of compound 1, anti-1), set B [doubly Boc-protected derivative of compound 1, (Boc)2-1], and set C (imidic acid tautomers of 
compound 1, tautomer-1), and the deprotected derivative of compound 1 are designated by the symbols , §, ■, and ӿ respectively. Peak 




































Figure A90. 1H NMR spectrum of the anti-rotamers of compound 1 in DMF-d7 solvent at 25 °C to 90 °C. Peaks associated with 
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